ZA200400342B - Cysteine mutants and methods for detecting ligand binding to biological molecules - Google Patents
Cysteine mutants and methods for detecting ligand binding to biological molecules Download PDFInfo
- Publication number
- ZA200400342B ZA200400342B ZA2004/00342A ZA200400342A ZA200400342B ZA 200400342 B ZA200400342 B ZA 200400342B ZA 2004/00342 A ZA2004/00342 A ZA 2004/00342A ZA 200400342 A ZA200400342 A ZA 200400342A ZA 200400342 B ZA200400342 B ZA 200400342B
- Authority
- ZA
- South Africa
- Prior art keywords
- residue
- seq
- cysteine
- tbm
- reference value
- Prior art date
Links
- 235000018417 cysteine Nutrition 0.000 title claims description 119
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims description 100
- 238000000034 method Methods 0.000 title claims description 63
- 239000003446 ligand Substances 0.000 title description 55
- 210000004027 cell Anatomy 0.000 claims description 140
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 235000018102 proteins Nutrition 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 57
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 39
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims description 33
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 claims description 30
- 108010002350 Interleukin-2 Proteins 0.000 claims description 23
- 102000000588 Interleukin-2 Human genes 0.000 claims description 23
- 102000004388 Interleukin-4 Human genes 0.000 claims description 23
- 108090000978 Interleukin-4 Proteins 0.000 claims description 23
- 102000005962 receptors Human genes 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 22
- 150000001945 cysteines Chemical class 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 18
- 102100029855 Caspase-3 Human genes 0.000 claims description 17
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 15
- 230000000052 comparative effect Effects 0.000 claims description 14
- 108091008611 Protein Kinase B Proteins 0.000 claims description 13
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 12
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims description 12
- -1 methyl carbon Chemical compound 0.000 claims description 12
- 108090000397 Caspase 3 Proteins 0.000 claims description 11
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 11
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 11
- 102100021257 Beta-secretase 1 Human genes 0.000 claims description 10
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 9
- 102000020233 phosphotransferase Human genes 0.000 claims description 9
- 108010029697 CD40 Ligand Proteins 0.000 claims description 8
- 102100032937 CD40 ligand Human genes 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 102000003816 Interleukin-13 Human genes 0.000 claims description 8
- 108090000176 Interleukin-13 Proteins 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 102100023326 M-phase inducer phosphatase 1 Human genes 0.000 claims description 7
- 108010000499 Thromboplastin Proteins 0.000 claims description 7
- 229940060587 alpha e Drugs 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 6
- 125000002228 disulfide group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 102100035904 Caspase-1 Human genes 0.000 claims description 5
- 108090000426 Caspase-1 Proteins 0.000 claims description 5
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 5
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 5
- 101000624625 Homo sapiens M-phase inducer phosphatase 1 Proteins 0.000 claims description 5
- 108010002459 HIV Integrase Proteins 0.000 claims description 4
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims description 4
- 101150071577 chi2 gene Proteins 0.000 claims description 4
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 claims description 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 2
- 101700056750 PAK1 Proteins 0.000 claims description 2
- 108090000315 Protein Kinase C Proteins 0.000 claims description 2
- 101710125350 Serine/threonine-protein kinase N1 Proteins 0.000 claims description 2
- 238000012617 force field calculation Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 claims 1
- 102100030859 Tissue factor Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 109
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 79
- 238000003752 polymerase chain reaction Methods 0.000 description 63
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 60
- 230000035772 mutation Effects 0.000 description 58
- 239000013612 plasmid Substances 0.000 description 58
- 239000000872 buffer Substances 0.000 description 54
- 208000022971 Tuberculous meningitis Diseases 0.000 description 52
- 208000001223 meningeal tuberculosis Diseases 0.000 description 52
- 108091034117 Oligonucleotide Proteins 0.000 description 42
- 239000013615 primer Substances 0.000 description 41
- 229960000723 ampicillin Drugs 0.000 description 38
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 38
- 239000000047 product Substances 0.000 description 38
- 102000053602 DNA Human genes 0.000 description 37
- 229940088598 enzyme Drugs 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000011780 sodium chloride Substances 0.000 description 30
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 29
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000013598 vector Substances 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 239000007983 Tris buffer Substances 0.000 description 24
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 21
- 102100040247 Tumor necrosis factor Human genes 0.000 description 20
- 125000004429 atom Chemical group 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 19
- 229920001817 Agar Polymers 0.000 description 18
- 239000008272 agar Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 239000002585 base Substances 0.000 description 18
- 238000010367 cloning Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000002703 mutagenesis Methods 0.000 description 18
- 231100000350 mutagenesis Toxicity 0.000 description 18
- 101100400991 Caenorhabditis elegans mek-1 gene Proteins 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 238000012163 sequencing technique Methods 0.000 description 17
- 102000003960 Ligases Human genes 0.000 description 16
- 108090000364 Ligases Proteins 0.000 description 16
- 238000005119 centrifugation Methods 0.000 description 16
- 239000008188 pellet Substances 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 15
- 108020004682 Single-Stranded DNA Proteins 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000282326 Felis catus Species 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 150000003573 thiols Chemical class 0.000 description 13
- 101100400994 Caenorhabditis elegans mek-2 gene Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 108700000707 bcl-2-Associated X Proteins 0.000 description 12
- 102000055102 bcl-2-Associated X Human genes 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 102000012410 DNA Ligases Human genes 0.000 description 11
- 108010061982 DNA Ligases Proteins 0.000 description 11
- 102100031780 Endonuclease Human genes 0.000 description 11
- 108010042407 Endonucleases Proteins 0.000 description 11
- 239000011543 agarose gel Substances 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 102000001267 GSK3 Human genes 0.000 description 10
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 229940124647 MEK inhibitor Drugs 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 229920000936 Agarose Polymers 0.000 description 8
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 8
- 108010021466 Mutant Proteins Proteins 0.000 description 8
- 102000008300 Mutant Proteins Human genes 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 229940028885 interleukin-4 Drugs 0.000 description 8
- 231100000219 mutagenic Toxicity 0.000 description 8
- 230000003505 mutagenic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010023321 Factor VII Proteins 0.000 description 7
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 7
- 102100034343 Integrase Human genes 0.000 description 7
- 108010061833 Integrases Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 7
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 210000003000 inclusion body Anatomy 0.000 description 7
- 101150024228 mdm2 gene Proteins 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 description 6
- 102100023804 Coagulation factor VII Human genes 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 6
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 6
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 6
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000008051 TBE buffer Substances 0.000 description 6
- 102000002262 Thromboplastin Human genes 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940012413 factor vii Drugs 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 108090000613 Cathepsin S Proteins 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 102100023132 Transcription factor Jun Human genes 0.000 description 4
- 102220470306 Tryptase delta_D48C_mutation Human genes 0.000 description 4
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 102220346421 c.92C>A Human genes 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 4
- 229940099500 cystamine Drugs 0.000 description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960003151 mercaptamine Drugs 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 102220005308 rs33960931 Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 3
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 3
- 102000051485 Bcl-2 family Human genes 0.000 description 3
- 108700038897 Bcl-2 family Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 3
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 102000005497 Thymidylate Synthase Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000002019 disulfides Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229960004198 guanidine Drugs 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102220233973 rs1060500235 Human genes 0.000 description 3
- 102200007101 rs34049451 Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- KUOGTDMKRNWKQW-UHFFFAOYSA-H trimagnesium hexachloride Chemical compound [Mg+2].[Mg+2].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-] KUOGTDMKRNWKQW-UHFFFAOYSA-H 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 2
- 101150107888 AKT2 gene Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100035654 Cathepsin S Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108030004793 Dual-specificity kinases Proteins 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 2
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 2
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 238000012218 Kunkel's method Methods 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 241000255969 Pieris brassicae Species 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 description 2
- 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 2
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 2
- 101100236866 Xenopus laevis mdm2 gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000012219 cassette mutagenesis Methods 0.000 description 2
- 108010046616 cdc25 Phosphatases Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000044297 human BACE1 Human genes 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000006951 hyperphosphorylation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102220297958 rs1402178514 Human genes 0.000 description 2
- 102220341170 rs199565868 Human genes 0.000 description 2
- 102220101292 rs536400111 Human genes 0.000 description 2
- 102220250911 rs61758066 Human genes 0.000 description 2
- 102220273993 rs780223957 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 238000012807 shake-flask culturing Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
- 241000801930 Apterona helix Species 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 102400001242 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
- 101100139845 Caenorhabditis elegans rac-2 gene Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 101710157591 Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101100405254 Drosophila melanogaster Nrg gene Proteins 0.000 description 1
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 229940121854 Factor VII inhibitor Drugs 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000038624 GSKs Human genes 0.000 description 1
- 101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 1
- 102220563838 Glucagon receptor_C25S_mutation Human genes 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000777461 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 17 Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
- 101000911753 Homo sapiens Protein FAM107B Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 101710093458 ICOS ligand Proteins 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 101710138028 Integrin-linked protein kinase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101150078498 MYB gene Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 101100325747 Mus musculus Bak1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010032109 Non-Receptor Type 12 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 108010026809 Peptide deformylase Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102220624649 Pleckstrin homology domain-containing family O member 1_K42C_mutation Human genes 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 102220557327 Proprotein convertase subtilisin/kexin type 4_C56A_mutation Human genes 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100026983 Protein FAM107B Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101100368917 Schizosaccharomyces pombe (strain 972 / ATCC 24843) taz1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000003592 T-IEL Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 102100033020 Tyrosine-protein phosphatase non-receptor type 12 Human genes 0.000 description 1
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 1
- 101150037250 Zhx2 gene Proteins 0.000 description 1
- 102220606887 Zinc finger protein Gfi-1b_L75C_mutation Human genes 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000008003 autocrine effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 1
- 108700039689 bcl-2 Homologous Antagonist-Killer Proteins 0.000 description 1
- 101150022111 bel2 gene Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 102220359619 c.62T>C Human genes 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 101150055276 ced-3 gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000005793 childhood medulloblastoma Diseases 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940118526 interleukin-9 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108010013773 recombinant FVIIa Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200146364 rs141090506 Human genes 0.000 description 1
- 102220135149 rs144300387 Human genes 0.000 description 1
- 102220046301 rs148061139 Human genes 0.000 description 1
- 102220286953 rs1554569661 Human genes 0.000 description 1
- 102200071196 rs1800730 Human genes 0.000 description 1
- 102200000769 rs193922748 Human genes 0.000 description 1
- 102220005306 rs33926796 Human genes 0.000 description 1
- 102220120573 rs368277209 Human genes 0.000 description 1
- 102220075834 rs369735050 Human genes 0.000 description 1
- 102220316799 rs372115693 Human genes 0.000 description 1
- 102200131346 rs58436778 Human genes 0.000 description 1
- 102220309853 rs760797899 Human genes 0.000 description 1
- 102220264931 rs774900322 Human genes 0.000 description 1
- 102220070931 rs794728600 Human genes 0.000 description 1
- 102220093887 rs876659717 Human genes 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035892 strand transfer Effects 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- PJMJFVQKDBRMIP-UHFFFAOYSA-N tetraphenylarsonium Chemical compound C1=CC=CC=C1[As+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PJMJFVQKDBRMIP-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000000293 three-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Description
CYSTEINE MUTANTS AND METHODS FOR DETECTING LIGAND BINDING TO
BIOLOGICAL MOLECULES
) BACKGROUND 0 5 The drug discovery process usually beings with massive functional screening of compound libraries he to identify modest affinity leads (Ky ~ 1 to 10 pM) for subsequent medicinal chemistry optimization. However, not all targets of interest are amenable to such screening. In some cases, an assay that is amenable to high throughput screening is not available. In other cases, the target can have multiple binding modes such that the results of such screens are ambiguous and difficult to interpret. Still in other cases, the assay conditions for high throughput screening are such that they are prone to artifacts. As a result, alternative methods for ligand discovery are needed that to not necessarily rely on functional assays. The present invention provides such methods.
The present invention relates generally to variants of target biological molecules ("TBMs") and to methods of making and using the same to identify ligands of TBMs. More specifically, the invention relates to individual variant TBMs and sets of variant TBMs, each of which represents a modified version of a protein of interest where a thiol has been introduced at or near a site of interest. Ligands of TBMs are identified in part through the formation of a covalent bond between a potential ligand and a reactive thiol on the TBM.
Figure 1 schematically illustrates one embodiment of the tethering method wherein the target is a protein and the covalent bond is a disulfide. A thiol-containing protein is reacted with a plurality of ligand candidates. A ligand candidate that possesses an inherent binding affinity for the target is identified and a ligand is made comprising the identified binding determinant (represented by the circle).
Figure 2 is a representative example of a tethering experiment. Figure 2A is the deconvoluted mass spectrum of the reaction of thymidylate synthase ("TS") with a pool of 10 different ligand candidates with little or no binding affinity for TS. Figure 2B is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates ) possesses an inherent binding affinity to the enzyme. . Figure 3 shows three illustrative examples of the distribution pattern of the residues that are each mutated to a cysteine. Figure 3A is an example where the residues are distributed about a single site of interest. The structure is of the core domain of HIV integrase with the portion comprising the site of interest shaded in dark gray. Figure 3B is an example where the residues are distributed about two sites of interest. The structure is of the human interleukin-1 receptor with the portions comprising the two sites of interested shaded in dark gray. Figure 3C is an example where the residues are distributed throughout the surface of a protein. The structure is the trimeric structure of human TNF-a.
Figure 4 shows the side chain rotamers of cysteines in A) B-sheets and B) a-helices.
The present invention relates generally to variants of target biological molecules ("TBMs") and to methods of making and using the same to identify ligands of TBMs.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
References, such as Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J.
Wiley & Sons (New York, NY 1994), and March, Advanced Organic Chemistry Reactions,
Mechanisms and Structure 4th ed., John Wiley & Sons (New York, NY 1992), provide one skilled in the art with a general guide to many of the terms used in the present application. ni
The definition of terms used herein include:
The term “aliphatic” or “unsubstituted aliphatic” refers to a straight, branched, cyclic, or polycyclic hydrocarbon and includes alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.
The term “alkyl” or “unsubstituted alkyl” refers to a saturated hydrocarbon.
The term “alkenyl” or “unsubstituted alkenyl” refers to a hydrocarbon with at least one carbon- carbon double bond.
The term “alkynyl” or “unsubstituted alkynyl” refers to a hydrocarbon with at least one carbon- carbon triple bond.
The term “aryl” or “unsubstituted aryl” refers to mono or polycyclic unsaturated moieties having at least one aromatic ring. The term includes heteroaryls that include one or more heteroatoms within ) the at least one aromatic ring. Illustrative examples of aryl include: phenyl, naphthyl, \ tetrahydronaphthyl, indanyl, indenyl, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazoly, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
The term “substituted” when used to modify a moiety refers to a substituted version of the moiety where at least one hydrogen atom is substituted with another group including but not limited to: aliphatic; aryl, alkylaryl, F, Cl, I, Br, -OH; -NO,; -CN; -CFs;; -CH,CF,; -CH,Cl; -CH,OH; . -CH,CH,0H; -CH,NH,; -CH,SO,CH;; -OR*; -C(O)R*; -COOR*; -C(O)N(R"), -OC(O)R%; -OCOORY; -OC(O)N(R"),; -N(R"),; -S(O),R*; and -NR*C(O)R* where each occurrence of R* is # independently hydrogen, substituted aliphatic, unsubstituted aliphatic, substituted aryl, or unsubstituted aryl. Additionally, substitutions at adjacent groups on a moiety can together form a cyclic group.
The term “antagonist” is used in the broadest sense and includes any ligand that partially or fully blocks, inhibits or neutralizes a biological activity exhibited by a target, such as a TBM. In a similar manner, the term “agonist” is used in the broadest sense and includes any ligand that mimics a biological activity exhibited by a target, such as a TBM, for example, by specifically changing the function or expression of such TBM, or the efficiency of signaling through such TBM, thereby altering (increasing or inhibiting) an already existing biological activity or triggering a new biological activity.
The term "ligand" refers to an entity that possesses a measurable binding affinity for the target. In general, a ligand is said to have a measurable affinity if it binds to the target with a K4 or a K; of less than about 100 mM, preferably less than about 10 mM, and more preferably less than about 1 mM. In preferred embodiments, the ligand is not a peptide and is a small molecule. A ligand is a small molecule if it is less than about 2000 daltons in size, usually less than about 1500 daltons in size. In more preferred embodiments, the small molecule ligand is less than about 1000 daltons in size, usually less than about 750 daltons in size, and more usually less than about 500 daltons in size.
The term "ligand candidate” refers to a compound that possesses or has been modified to possess a reactive group that is capable of forming a covalent bond with a complimentary or compatible reactive group on a target. The reactive group on either the ligand candidate or the target can be masked with, for example, a protecting group.
The term “polynucleotide”, when used in singular or plural, generally refers to any , polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-
stranded or include single- and double-stranded regions. In addition, the term “polynucleotide” as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some ‘
S of the molecules. One of the molecules of a triple-helical region often 1s an oligonucleotide. The term “polynucleotide” specifically includes DNAs and RNAs that contain one or more modified . bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, are included within the term “polynucleotides” as defined herein. In general, the term “polynucleotide” embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.
The phrase “protected thiol” as used herein refers to a thiol that has been reacted with a group or molecule to form a covalent bond that renders it less reactive and which may be deprotected to regenerate a free thiol.
The phrase “reversible covalent bond” as used herein refers to a covalent bond that can be broken, preferably under conditions that do not denature the target. Examples include, without limitation, disulfides, Schiff-bases, thioesters, coordination complexes, boronate esters, and the like.
The phrase “reactive group” is a chemical group or moiety providing a site at which a covalent bond can be made when presented with a compatible or complementary reactive group. Illustrative examples are -SH that can react with another -SH or -SS- to form a disulfide; an -NH, that can react with an activated -COOH to form an amide; an -NH, that can react with an aldehyde or ketone to form a Schiff base and the like.
The phrase “reactive nucleophile” as used herein refers to a nucleophile that is capable of forming a covalent bond with a compatible functional group on another molecule under conditions that do not denature or damage the target. The most relevant nucleophiles are thiols, alcohols, and amines. .
Similarly, the phrase “reactive electrophile" as used herein refers to an electrophile that is capable of forming a covalent bond with a compatible functional group on another molecule, preferably ‘ under conditions that do not denature or otherwise damage the target. The most relevant electrophiles are imines, carbonyls, epoxides, aziridies, sulfonates, disulfides, activated esters, activated carbonyls, and hemiacetals. a
The phrase "site of interest" refers to any site on a target on which a ligand can bind. For example, when the target is an enzyme, the site of interest can include amino acids that make contact with, or lie within about 10 Angstroms (more preferably within about 5 Angstroms) of a bound substrate, . inhibitor, activator, cofactor, or allosteric modulator of the enzyme. When the enzyme is a 5S protease, the site of interest includes the substrate binding channel from S6 to S6', residues involved i: in catalytic function (e.g. the catalytic triad and oxy anion hole), and any cofactor (e.g. metal such as Zn) binding site. When the enzyme is a protein kinase, the site of interest includes the substrate- binding channel in addition to the ATP binding site. When the enzyme is a dehydrogenease, the site of interest includes the substrate binding region as well as the site occupied by NAD/NADH. 10 When the enzyme is a hydralase such as PDE4, the site of interest includes the residues in contact with cAMP as well as the residues involved in the binding of the catalytic divalent cations.
The terms “target,” "Target Molecule,” and "TM" are used interchangeably and in the broadest sense, and refer to a chemical or biological entity for which the binding of a ligand has an effect on 15 the function of the target. The target can be a molecule, a portion of a molecule, or an aggregate of molecules. The binding of a ligand may be reversible or irreversible. Specific examples of target molecules include polypeptides or proteins such as enzymes and receptors, transcription factors, ligands for receptors such growth factors and cytokines, immunoglobulins, nuclear proteins, signal transduction components (e.g., kinases, phosphatases), polynucleotides, carbohydrates, 20 glycoproteins, glycolipids, and other macromolecules, such as nucleic acid-protein complexes, chromatin or ribosomes, lipid bilayer-containing structures, such as membranes, or structures derived from membranes, such as vesicles. The definition specifically includes Target Biological
Molecules ("TBMs") as defined below. 25 A “Target Biological Molecule” or “TBM” as used herein refers to a single biological molecule or a plurality of biological molecules capable of forming a biologically relevant complex with one another for which a small molecule agonist or antagonist has an effect on the function of the TBM.
In a preferred embodiment, the TBM is a protein or a portion thereof or that comprises two or more amino acids, and which possesses or is capable of being modified to possess a reactive group that is 30 capable of forming a covalent bond with a compound having a complementary reactive group. 3 Preferred TBMs include: cell surface and soluble receptors and their ligands; steroid receptors; hormones; immunoglobulins; clotting factors; nuclear proteins; transcription factors; signal . transduction molecules; cellular adhesion molecules, co-stimulatory molecules, chemokines, molecules involved in mediating apoptosis, enzymes, and proteins associated with DNA and/or 35 RNA synthesis or degradation.
Many TBMs are those participate in a receptor-ligand binding interaction and can be either member of a receptor-ligand pair. Illustrative examples of growth factors and their respective receptors include those for: erythropoietin (EPO), thrombopoietin (TPO), angiopoietin (ANG), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF). . epidermal growth factor (EGF), heregulin-a and heregulin-g, vascular endothelial growth factor (VEGF), placental growth factor (PLGF), transforming growth factors (TGF-a and TGF-p), nerve . growth factor (NGF), neurotrophins, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), hepatocyte growth factor (HGF), and insulin-like growth factor 1 (IGF-1). Illustrative examples of hormones and their respective receptors include those for: growth hormone, prolactin, placental lactogen (LPL), msulin, follicle stimulating hormone (FSH), luteinizing hormone (LH), and neurokinin-1.
Illustrative examples of cytokines and their respective receptors include those for: ciliary neurotrophic factor (CNTF), oncostatin M (OSM), TNF-a; CD40L, stem cell factor (SCF); interleukin-1, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-9, interleukin-13, and interleukin-18.
Other TBMs include: cellular adhesion molecules such as CD2, CD11a, LFA-1, LFA-3, ICAM-S,
VCAM-1, VCAM-5, and VLA-4; costimulatory molecules such as CD28, CTLA-4, B7-1; B7-2,
ICOS, and B7RP-1; chemokines such as RANTES and MIP1b; apoptosis factors such as APAF-1, p53, bax, bak, bad, bid, and c-abl; anti-apoptosis factors such as bel2, bel-x(L), and mdm2; transcription modulators such as AP-1 and AP-2; signaling proteins such as TRAF-1, TRAF-2,
TRAF-3, TRAF-4, TRAF-5, and TRAF-6; and adaptor proteins such as grb2, cbl, she, nck, and crk
Enzymes are another class of preferred TBMs and can be categorized in numerous ways including as: allosteric enzymes; bacterial enzymes (isoleucyl tRNA synthase, peptide deformylase, DNA gyrase, and the like); fungal enzymes (thymidylate synthase and the like); viral enzymes (HIV integrase, HSV protease, Hepatitis C helicase, Hepatitis C protease, rhinovirus protease and the like); kinases (serine/threonine, tyrosine, and dual specificity); phosphatases (serine/threonine, tyrosine, and dual specificity); and proteases (aspartyl, cysteine, metallo, and serine proteases).
Notable subclasses of enzymes include: kinases such as Lck, Syk, Zap-70, JAK, FAK, ITK, BTK,
MEK, MEKK, GSK-3, Raf, tgf-p-activated kinase-1 (TAK-1), PAK-1, cdk4, Akt, PKC 6, IKK B, .
IKK-2, PDK, ask, nik, MAPKAPK, p90rsk, p70s6k, and PI3-K (p85 and pl110 subunits); phosphatases such as CD45, LAR, RPTP-a, RPTP-y4, Cdc25A, kinase-associated phosphatase, map ' kinase phosphatase-1, PTP-1B, TC-PTP, PTP-PEST, SHP-1 and SHP-2; caspases such as caspases- 1,-3,-7,-8,-9, and -11; and cathespins such as cathepsins B, F,K, L, S, and V. Other enzymatic targets include: BACE, TACE, cytosolic phospholipase A2 (cPLA2), PARP, PDE I-VII, Rac-2,
CD26, inosine monophosphate dehydrogenase, 15-lipoxygenase, acetyl CoA carboxylase,
adenosylmethionine decarboxylase, dihydroorotate dehydrogenase, leukotriene A4 hydrolase, and nitric oxide synthase.
The present invention relates generally to variants of target biological molecules ("TBMs") and to 4 methods of making and using the same to identify ligands of the TBMs. In preferred embodiments, the TBMs are proteins and the variants are cysteine mutants thereof wherein a naturally occurring non-cysteine residue of a TBM is mutated into a cysteine residue. The non-native cysteine provides a reactive group on the TBM for use in tethering.
Tethering is a method of ligand identification that relies upon the formation of a covalent bond between a reactive group on a target and a complimentary reactive group on a potential ligand, and is described in U.S. Patent No. 6,335, 155, PCT Publication Nos. WO 00/00823 and WO 02/42773, :
Erlanson et al, Proc. Nat. Acad. Sci. USA 97: 9367-9372 (2000), and U.S. Serial No. 10/121,216 entitled METHODS FOR LIGAND DISCOVERY by inventors Daniel Erlanson, Andrew Braisted, and James Wells (corresponding PCT Application No. US02/13061). The resulting covalent complex is termed a target-ligand conjugate. Because the covalent bond is formed at a pre- determined site on the target (e.g., a native or non-native cysteine), the stoichiometry and binding location are known for ligands that are identified by this method.
Once formed, the ligand portion of the target-ligand conjugate can be identified using a number of methods. In preferred embodiments, mass spectroscopy is used. The target-ligand can be detected directly in the mass spectrometer or fragmented prior to detection. Alternatively, the ligand can be liberated from the target-ligand conjugate within the mass spectrophotometer and subsequently identified. In other embodiments, alternate detection methods are used including to but not limited to: chromatography, labeled probes (fluorescent, radioactive, etc.), nuclear magnetic resonance ("NMR"), surface plasmon resonance (e.g., BIACORE), capillary electrophoresis, X-ray crystallography and the like. In still other embodiments, functional assays can also be used when the binding occurs in an area essential for what the assay measures. } A schematic representation of one embodiment of the tethering method where the target is a protein and the covalent bond is a disulfide is shown in Figure 1. A thiol containing protein is reacted with ; a plurality of ligand candidates. In this embodiment, the ligand candidates possess a masked thiol in the form of a disulfide of the formula -SSR' where R' is unsubstituted C,-C), alkyl, substituted C,-Cyo alkyl, unsubstituted aryl or substituted aryl. In certain embodiments, R' is selected to enhance the solubility of the potential ligand candidates. As shown, a ligand candidate that possesses an inherent binding affinity for the target is identified and a corresponding ligand that does not include the disulfide moiety is made comprising the identified binding determinant (represented by the circle).
Figure 2 illustrates two representative tethering experiments where a target enzyme. E coli thymidylate synthase, is contacted with ligand candidates of the formula 5
H wherein R° is the variable moiety among this pool of library members and is unsubstituted aliphatic, substituted aliphatic, unsubstituted aryl, or substituted aryl. Like all TS enzymes, E. coli TS has an active site cysteine (Cys146) that can be used for tethering. Although the E. coli TS also includes four other cysteines, these cysteines are buried and were found not to be reactive in tethering experiments. For example, in an initial experiment, wild type E. coli TS and the C146S mutant (wherein the cysteine at position 146 has been mutated to serine) were contacted with cystamine,
H,NCH,CH,SSCH,CH;NH,. The wild type TS enzyme reacted cleanly with one equivalent of cystamine while the mutant TS did not react indicating that the cystamine was reacting with and was selective for Cys146.
Figure 2A is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS. In the absence of any binding interactions, the equilibrium in the disulfide exchange reaction between TS and an individual ligand candidate is to the unmodified enzyme. This is schematically illustrated by the following equation.
TS-Cys,u-SH + fC 1 NAS eA: — TS Cou SS ANH + TS-Cysiee-SS7\AH2
H o
As expected, the peak that corresponds to the unmodified enzyme is one of two most prominent peaks in the spectrum. The other prominent peak is TS where the thiol of Cys146 has been modified with cysteamine. Although this species is not formed to a significant extent for any individual library member, the peak is due to the cumulative effect of the equilibrium reactions for each member of the library pool. When the reaction is run in the presence of a thiol-containing reducing agent such as 2-mercaptoethanol, the active site cysteine can also be modified with the reducing agent. Because cysteamine and 2-mercaptoethanol have similar molecular weights, their respective disulfide bonded TS enzymes are not distinguishable under the conditions used in this . experiment. The small peaks on the right correspond to discreet library members. Notably, none of these peaks are very prominent. Figure 2A is characteristic of a spectrum where none of the ligand candidates possesses an inherent binding affinity for the target.
Figure 2B is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme. As can be seen, the most prominent peak is the one that corresponds to TS where the thiol ; of Cys146 has been modified with the N-tosyl-D-proline compound. This peak dwarfs all others including those corresponding to the unmodified enzyme and TS where the thiol of Cys146 has % been modified with cysteamine. Figure 2B is an example of a mass spectrum where tethering has captured a moiety that possesses a strong inherent binding affinity for the desired site.
The representative tethering experiments of Figure 2 were performed on a TBM that already possessed a naturally occurring cysteine at a site of interest (Cys146 located in the active site of the
E. coli TS enzyme). However, because TBMs do not always possess a naturally occurring cysteine at or near a site of interest, the present invention provides cysteine mutant variants of TBMs as well as methods for making the same.
Thus, in one aspect of the present invention, a set comprising at least one cysteine mutant of a protein TBM is provided wherein a naturally occurring non-cysteine residue at or near a site of interest is mutated to a cysteine residue. In one embodiment, the set comprises a plurality of cysteine mutants of a protein TBM wherein each mutant has a different naturally occurring non- cysteine residue that is mutated to a cysteine residue. In another embodiment, the set comprises at least three cysteine mutants of a protein TBM wherein each mutant has a different naturally occurring non-cysteine residue that is mutated to a cysteine residue. In yet another embodiment, the set comprises at least five cysteine mutants of a protein TBM wherein each mutant has a different naturally occurring non-cysteine residue that is mutated to a cysteine residue. In still yet another embodiment, the set comprises at least ten cysteine mutants of a protein TBM wherein each mutant has a different naturally occurring non-cysteine residue that is mutated to a cysteine residue.
In another aspect of the present invention, methods are provided for identifying residues that are suitable for mutating into cysteines. In preferred embodiments, a model or an experimentally derived three-dimensional structure (e.g., X-ray or 3D NMR) of a TBM is used to help identify residues that are suitable for mutating into cysteines. If a structure of the TBM of interest in . unavailable, then a three-dimensional structure of a related or homologous TBM can be used as a stand-in. Once suitable residues are identified using the stand-in structure, then methods known in , the art, such as sequence alignment, are used to identify the corresponding residues in the TBM of interest. In general, the methods described below for identifying suitable residues for mutating into cysteines can be used alone or in any combination with each other.
In one method, the local backbone conformation of a candidate residue is determined and a database of experimentally solved structures is searched for examples of a disulfide-bonded cysteine having the same or similar local backbone conformation as the candidate residue. Any combination of a residue's backbone atoms (N, C,, C and QO) can be used to determine the local conformation. The likelihood that the TBM accepts the cysteine mutation improves as more examples are found in a database of known disulfide-bonded cysteines in the same or similar local : backbone conformation. Experimentally solved structures are available from many sources including the Protein Databank ("PDB") which can be found on the Internet at hup:/www.rcsb.or and the Protein Structure Database which can be found on the Internet at http.//www.pcs.com. Lists of unique, high-resolution protein chains (grouped by structures having a certain resolution and R- factor) that can be used to compile a database of experimentally solved structures are found on the
Internet at http://www fcec.edu/researchvlabs/dunbrack/culiedpdb.html. In general, the local environment of a candidate residue includes the candidate residue itself and at least one residue preceding or following the candidate residue in sequence. A conformation is considered the same or similar if the root mean square deviation ("RMSD") of the atoms being compared is less than or equal to about1.0 Angstrom’, more preferably, less than or equal to about 0.75 Angstrom?, and even more preferably, less than or equal to about 0.5 Angstrom’.
In one embodiment, the method comprises: a) obtaining a set of coordinates of a three dimensional structure of a protein TBM having n number of residues; b) selecting a candidate residue i on the three dimensional structure of the TBM wherein the candidate residue i is the ith residue where i is a number between 1 and n and residue i 1s not a cysteine; c) selecting a residue j where residue ; is adjacent to residue i in sequence; d) determining a candidate reference value wherein the candidate reference value is a spatial relationship between residue i and residue j; €) obtaining a database comprising sets of coordinates of disulfide-containing protein fragments wherein each fragment comprises at least a disulfide-bonded cysteine and a first adjacent residue where the disulfide-bonded cysteine and the first adjacent residue share the same sequential relationship as residue i and residue J; . f) determining a comparative reference value for each fragment wherein the comparative reference value is the corresponding spatial relationship between the disulfide-bonded . cysteine and the first adjacent residue as the candidate reference value is between residue i and J; and,
g) determining a score wherein the score is a measure of the number of fragments in the database that possess a comparative reference value that is the same or similar to the candidate reference value.
In another embodiment, the method further comprises ’ selecting a residue k where residue is adjacent to residue i in sequence and k is not j; and wherein the candidate reference value is a spatial relationship between residue i, residue j, and residue k; each fragment comprises at least a disulfide-bonded cysteine, a first adjacent residue, and a second adjacent residue where the disulfide-bonded cysteine and the first and second adjacent residues share the same sequential relationship as residue i, residue J, and residue k; and the comparative reference value is the corresponding spatial relationship between the disulfide bonded cysteine, the first adjacent residue, and the second adjacent residue as the candidate reference value is between residue i, residue j, and residue £.
In another embodiment, the method comprises: a) obtaining a set of coordinates of a three dimensional structure of a protein TBM having n number of residues; b) selecting a candidate residue i on the three dimensional structure of the TBM wherein the candidate residue i is the ith residue where i is a number between 1 and n and residue i is not a cysteine; c) selecting residue j and residue k£ wherein residue j and residue % are both adjacent in sequence to residue i; d) determining a candidate reference value wherein the candidate reference value is a spatial relationship of at least one backbone atom from each of residue i, residue J, and residue £; e) obtaining a database comprising sets of coordinates of disulfide-containing protein fragments wherein each fragment comprises at least a disulfide-bonded cysteine, a first adjacent residue, and a second adjacent residue where the disulfide-bonded cysteine, the first adjacent residue, and the second adjacent residue share the same sequential relationship as residue i, residue . J, and residue k; f) determining a comparative reference value for each fragment wherein the ‘ comparative reference value is the corresponding spatial relationship between the disulfide-bonded cysteine, the first adjacent residue, and the second adjacent residue as the candidate reference value is between residue J, residue J, and residue k; and,
2) determining a score wherein the score is a measure of the number of fragments in the database that possess a comparative reference value that is the same or similar to the candidate reference value.
In another embodiment the spatial relationship comprises a dihedral angle. In vet another embodiment, the spatial relationship comprises a pair of phi psi angles. In another embodiment, the . spatial relationship comprises a distance between atoms of two residues. An illustrative example of a computer algorithm for identifying disulfide bonded pairs in a database such as the PDB and matching them with a residue that is a candidate for cysteine mutation is described in Example 1.
In another method, a site of interest is defined on a TBM and suitable residues for cysteine mutation are identified based on the location of the residue from the site of interest. In one embodiment, a suitable residue is a non-cysteine residue that is located within the site of interest. In another embodiment, a suitable residue is a non-cysteine residue that is located within about 5 A from the site of interest. In yet another embodiment, a suitable residue is a non-cysteine residue that is located within about 10 A from the site of interest. For the purposes of these measurements, any non-cysteine residue having at least one atom falling within about 5 A or about 10 A respectively from any atom of an amino acid within the site of interest is a suitable residue for mutating into a cysteine. A TBM can have one or multiple sites of interests. In some cases, a TBM has one site of interest and the set of residues that are each being mutated to a cysteine is clustered around this site of interest. In other cases, a TBM has at least two different sites of interest and the set of residues that are each being mutated to a cysteine is clustered around the at least two different sites of interest. Still in other cases, a TBM either does not possess a distinct site of interest or possesses multiple sites of interests such that the set of residues that are being mutated to a cysteine is dispersed throughout the protein surface. Figure 3 shows three illustrative examples of the distribution pattern of the residues that are each mutated to a cysteine
In another method, solvent accessibility is calculated for each non-cysteine residue of a TBM and used to identify suitable residues for cysteine mutation. Solvent accessibility can be calculated using any number of known methods including using standard numeric methods (Lee, B. &
Richards, F. M. J. Mol. Biol 55:379-400 (1971); Shrake, A. & Rupley, J. A. J. Mol. Biol. 79:351- : 371 (1973)) and analytical methods (Connolly, M. L. Science 221:709-713 (1983); Richmond, T. J.
J. Mol. Biol. 178:63-89 (1984)). In one embodiment, suitable residues for mutation include . residues where the combined surface area of the residue's atoms is equaled to or greater than about 20 A’. In another embodiment, suitable residues for mutation include residues where the combined surface area of the residue's atoms is equaled to or greater than about 30 A’. In yet another embodiment, suitable residues for mutation include residues where the combined surface area of the residue’s atoms is equaled to or greater than about 40 A”. ; In another method, suitable residues for cysteine mutation are identified by hydrogen bond analysis.
In one embodiment, a suitable residue is a non-cysteine residue that does not participate in any 3 hydrogen bond interaction. In another embodiment, a suitable residue is a non-cysteine residue whose side chain does not participate in any hydrogen bond interaction. In yet another embodiment, a suitable residue is a non-cysteine residue whose side chain does not participate in a hydrogen bond interaction with a backbone atom.
In another method, suitable residues for cysteine mutation are identified by rotamer analysis. In one embodiment, the method comprises: a) obtaining a three dimensional structure of a TBM having n number of residues and a site of interest; b) selecting a candidate residue i that is at or near the site of interest wherein the candidate residue i is the ith residue where i is a number between 1 and n and residue i is not a cysteine; c) generating a set of mutated TBM structures wherein each mutated TBM structure possesses a cysteine residue instead of residue i and wherein the cysteine residue is placed in a standard rotamer conformation; and, d) evaluating the set of mutated TBM structures.
In another embodiment, a standard rotamer conformation for cysteine comprises the set of cysteine rotamers enumerated by Ponders and Richards as described by Ponder, J. W. and Richards, F. M. J.
Mol. Biol. 193: 775-791 (1987).
In another embodiment, a standard rotamer conformation for cysteine comprises a chil angle selected from the group consisting of about 60°, about 180°, and about 300° and a chi2 angle selected from the group consisting of about 60°, about 120°, about 180°, about 270°, and about 300°.
In another embodiment, the method further comprises determining whether residue i is part of an a- . helix or a B-sheet and then selecting a standard rotamer conformation based on the assigned secondary structure. As shown in Figure 4, a different set of rotamers is preferred depending on the secondary structure that is assigned to the cysteine. Residue i is considered to be part of an a-helix if the phi psi angles of residues i-1, i, and i+1 are about 300+30° and 315+30° respectively, and is considered to be part of a B-sheet if the phi psi angles of residues i-1, i, and i+1 are about 240+30° and 120+30°. If residue i is part of an a-helix, then a standard rotamer conformation for cysteine comprises a chil chi2 pair selected from the group consisting of about 180° and about 60°; about 180° and about 270°; and about 300° and about 300°. If residue i is part of an f-helix, then a standard rotamer conformation for cysteine comprises a chil chi2 pair selected from the group . consisting of about 180° and about 60°; about 180° and about 180°; about 180° and about 270°: and about 300° and about 300°. :
In another embodiment, the set of mutated TBM structures are evaluated based upon whether an unfavorable steric contact is made. A residue is considered to be a suitable candidate for cysteine mutation if it can be substituted with at least one cysteine rotamer for which no unfavorable steric contact is made. An unfavorable steric contact is defined as interatomic distances that are less than about 80% of the sum of the van der Waals radii of the participating atoms. In one variation, only the backbone atoms of the TBM are considered for the purposes of determining whether the rotamers make an unfavorable contact with the TBM. In another variation, the backbone atoms and
GC; of the TBM are considered for the purposes of determining whether the rotamers make an unfavorable contact with the TBM.
In another embodiment, the set of mutated TBM structures are evaluated based on a force field calculation. Illustrative force field methods are described by, for example, Weer, S. J. er al. J.
Comput. Chem. 7: 230-252 (1986); Nemethy, G. ef al. J. Phys. Chem. 96: 6472-6484 (1992); and
Brooks, B.R. er al. J. Comput. Chem. 4: 187-217 (1983). All minimized conformations within about 10 kcal/mol or more preferably within about 5 kcal/mol, of the lowest-energy conformation are considered accessible.
In another embodiment, each mutated TBM structure possesses a cysteine that is capped with a S- methyl group (side chain is -CH,SSCH;) instead of residue i and wherein the capped cysteine residue is placed in a standard rotamer conformation for cysteine. A residue is considered to be a suitable candidate for cysteine mutation if it can be substituted with at least one rotamer that places the methyl carbon of the S-methyl group closer to the site of interest than the Cs.
In addition to adding one or more cysteines to a site of interest, it may be desirable to delete one or more naturally occurring cysteines (and replacing them with alanines for example) that are located outside of the site of interest. These mutants wherein one or more naturally occurring cysteines are . deleted or "scrubbed" comprise another aspect of the present invention. Various recombinant, chemical, synthesis and/or other techniques can be employed to modify a target such that it possesses a desired number of free thiol groups that are available for tethering. Such techniques include, for example, site-directed mutagenesis of the nucleic acid sequence encoding the target polypeptide such that it encodes a polypeptide with a different number of cysteine residues.
Particularly preferred is site-directed mutagenesis using polymerase chain reaction (PCR) amplification (see, for example, U.S. Pat. No. 4,683,195 issued 28 July 1987; and Current Protocols . In Molecular Biology, Chapter 15 (Ausubel ef al., ed., 1991). Other site-directed mutagenesis techniques are also well known in the art and are described, for example, in the following s publications: Ausubel et al., supra, Chapter 8, Molecular Cloning: A Laboratory Manual., 2nd edition (Sambrook et al., 1989); Zoller et al., Methods Enzymol. 100:468-500 (1983); Zoller &
Smith, DNA 3:479-488 (1984); Zoller et al., Nucl. Acids Res., 10:6487 (1987); Brake et al., Proc.
Natl. Acad. Sci. USA 81:4642-4646 (1984); Botstein et al., Science 229:1193 (1985); Kunkel et al.,
Methods Enzymol. 154:367-82 (1987), Adelman et al., DNA 2:183 (1983); and Carter et al., Nucl.
Acids Res., 13:4331 (1986). Cassette mutagenesis (Wells et al.,, Gene, 34:315 [1985]), and restriction selection mutagenesis (Wells ef al., Philos. Trans. R. Soc. London SerA, 317:415 [1986]) may also be used.
Amino acid sequence variants with more than one amino acid substitution may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously, using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from one another (e.g. separated by more than ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonucleotide is generated for each amino acid to be substituted.
The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant.
The invention is further illustrated by the following, non-limiting examples. Unless otherwise noted, all the standard molecular biology procedures are performed according to protocols described in (Molecular Cloning: A Laboratory Manual, vols. 1-3, edited by Sambrook, J., Fritsch,
EF, and Maniatis, T., Cold Spring Harbor Laboratory Press, 1989; Current Protocols in Molecular . Biology, vols. 1-2, edited by Ausbubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J.G.,
Smith, J., and Struhl, K., Wiley Interscience, 1987).
EXAMPLE 1
This example provides an illustrative computer algorithm written in FORTRAN for identifying disulfide pairs from the PDB that align with potential tethering mutants. A stepwise description of the program and the source code are described below.
First, a user supplies the name of the PDB file for the template protein, the residues of the fragment . to match, and the relative position of the cysteine within that fragment. Preferred values are 1-2 residues N- and C-terminal to a potential mutant site. For example, if residue Glu 200 of PTP1B is a candidate residue, then the user would specify the fragment from residues 198 to 202 with the cysteine at relative position 3.
Second, the program reads the template file, extracts the coordinates of the N,C,,C,0O atoms for the template residues, and determines the values of ¢ (C’-N-C,-C torsion) and y (N-C,-C-N’) for each of the template residues
Third, the program generates a “residue filter” based on the template ¢/y values. This filter is used to identify contiguous segments of a test protein that have ¢/y values matching those of the template residues to within a coarse (60°) tolerance. The filter also requires that the fragment must contain a cysteine at the appropriate position. In the PTP1B example above, the filter would identify 5-residue fragments of a test protein that roughly matched the backbone conformations of residues 198-202 of PTP1B and contained a cysteine in position 3.
Fourth, the rest of the program operates iteratively on a user-supplied list of test proteins provided in a simple text file. In one embodiment, this file contains approx. 2500 culled PDB chains. For each test structure: a) The program reads the coordinates, determines the sequence and ¢/y values for each residue, and identifies any contiguous chains that match the residue filter specified in step (3). b) The program checks to see that the cysteine residue in this fragment is participating in a disulfide bond. This is done by simple distance-and angle-based searching from the S, atom.
Fragments containing unpaired cysteines are rejected. c) For each fragment, the N,C,,C,0 atoms of the backbone are overlaid onto the : corresponding atoms from the template molecule (e.g. 198-202 of PTP1IB). If the backbone fits with an RMSD within a user-specified tolerance (typically 0.5-0.75 A), the overlaid coordinates of ’ this fragment along with its disulfide-bound partner are written to a file in PDB format. A log file is maintained of each “hit”, along with its RMSD value. The hits are viewed with a graphic program like Insight IT or PyMOL.
Source Code p c parameter (MAX_HITS = 10000) ¢ ) $INCLUDE tk.inc
SINCLUDE tk_functions.inc $INCLUDE rsm.inc 5 $INCLUDE rsm_functions.inc ¢
Record /hndl_rec/ data_handle, fragment_handle, template_handle
Record /atom_rec/ AtomRec
Record /res_rec/ ResRec
Record /res_filter/ FragmentFilter (MAX _RMS_ATOMS),
TemplateFilter (MAX_RMS_ATOMS)
Record /vec/ TemplateVecArray, FragmentVecArray, T1, T2
Dimension TemplateVecArray (MAX RMS_ATOMS),
FragmentVecArray (MAX_RMS_ATOMS) c
Integer*4 numTemplateRes, TemplateResList (MAX HITS), numHitRes,
HitResList (MAX_HITS), numTemplateVec, . CysIndex, FramelIndex, numSS, SS_1(MAX RES), SS_2 (MAX_RES), min_element, max_element, num_res, . icnt, jcnt, numFragAtom, FragAtomList (MAX RES), FragAtomIndex (MAX_RES),ires, jres, icys, cys_idx, jcys, . iatom, jatom, LISTin, PDBout, LOGout, len_name, len_root
Real*8 temp_min, temp_max, R2(3, 3), RMS cutoff, RMS_value,
RMS_WT (MAX_RES), angle_tol
Character listfile*80, full name*80, file_path+*80, file name*80, file_root*B0, file_ext*80, . structure _name*15, full structure_name*23, first_resnumber*7, charl*l, char3*l, tline*80, . token*80 c
LISTin = 9
PDBout = 10
LOGout = 11
FrameIndex = 1
RMS_ cutoff = 0.5 40 angle_tol = 60. do ires = 1, MAX RES
RMS _WT(ires) = 1.0 end do c 45 c...Get template information. c write (6,'(/,''Enter template PDB filename : '',$)') read (S,'(a)') tline if (.not.readPDBFile(tline, template_handle)) then 50 write (6,'(''ERROR: Unable to read template PDB file ###=#11)1) , return end if if (get_num_total residues (template_handle, num res)) continue c...get template residue numbers and convert to residue indeces * 55 10 write (6,'(5x,''Enter beginning, ending template residues : '',$)') read (5,'(a)') tline if (.not.get_token(tline, token)) goto 10 do icnt = 1, num_res if (getResData (template handle, FramelIndex, icnt, ResRec)) 60 continue if (ljust (ResRec.residue_number)) continue if (compstr (ResRec.residue number, token)) then ires = icnt goto 20 end if end do write (6,'(''ERROR: Unable to find residue '',aS50)') token goto 10 20 if (.not.get_token(tline, token)) goto 10 do icnt = 1, num_res if (getResData{template handle, FrameIndex, icnt, ResRec)) continue if (ljust (ResRec.residue_number)) continue if (compstr (ResRec.residue_number, token}) then jres = icnt goto 30 end if end do write (6,'(''ERROR: Unable to find residue '',aS50)') token goto 10 30 continue c numTemplateRes = jres - ires + 1 do icnt = 1, numTemplateRes
TemplateResList (icnt) = ires + icnt-1 end do if {(numTemplateRes .eq. 1) then cys_idx = 1 else write (6,'(Sx,''Enter relative position of cysteine : '',$)') read(s,*) cys_idx end if write (6,'{5x,''Enter the RMS cutoff : '',$)') read {5,*) RMS_cutoff ¢ ¢...Collect template residue atoms for fitting (N/CA/C/O). c numTemplatevVec = 0 do icnt = 1, numTemplateRes 40 ires = TemplateResList (icnt) if (.not.getAtomOfRes (template handle, FrameIndex, ires, 'N',
AtomRec)) then write (6,'(''ERROR: Unable to get N of template residue v1,i4)') ires 45 call exit else numTemplateVec = numTemplateVec + 1
TemplateVecArray (numTemplateVec) = AtomRec.vector end if 50 if (.not.getAtomOfRes (template handle, FramelIndex, ires, 'CA’,
AtomRec)) then write (6,'(''ERROR: Unable to get CA of template residue * '1,i4)') ires call exit 55 else : numTemplateVec = numTemplateVec + 1
TemplateVecArray (numTemplateVec) = AtomRec.vector end if if (.not.getAtomOfRes (template handle, FrameIndex, ires, 'C', 60 AtomRec)) then write (6,'(''ERROR: Unable to get C of template residue ‘',1i4)') ires call exit else
S numTemplateVec = numTemplateVec + 1
TemplateVecArray (numTemplateVec) = AtomRec.vector ’ end if if (.not.getAtomOfRes (template_handle, FrameIndex, ires, '0O’,
AtomRec)) then v 10 write (6,'('’'ERROR: Unable to get O of template residue '',i4)') ires call exit else numTemplateVec = numTemplateVec + 1
TemplateVecArray (numTemplateVec) = AtomRec.vector end if end do c c...Construct residue filter based on internal angles from the template. c¢ if (.not. initializeResFilter (FragmentFilter, MAX_RMS_ATOMS)}) then write(6, '(2X, ''ERROR: Unable to make residue-filter record'')') call exit end if
FragmentFilter (1) .seq_len = numTemplateRes
FragmentFilter (1) .start_ residue = 2 do icnt = 1, numTemplateRes ires = TemplateResList (icnt) if (.not.GetResData (template handle, FrameIndex, ires, ResRec)) then write (6,'(''ERROR: Unable to get record for residue '',i4)') ires call exit end if
FragmentFilter (icnt) .phi_val = ResRec.phi_val
FragmentFilter (icnt) .phi_tol = angle_tol
FragmentFilter (icnt) .psi_val = ResRec.psi_val
FragmentFilter (icnt).psi_tol = angle_tol 40 end do
FragmentFilter (cys_idx) .residue_name = 'CYS' if (returnTrajectory(template_handle)) continue c call getenv ('RSM_PDB_LISTFILE', listfile) 45 if (listfile.eq.' ') then write (6,'(/,''Enter structure listfile : '',$)"') read (5,'(a)') listfile end if open (file=listfile, unit=LISTin, status="old") 50 «¢ write (6,'(/,''Enter output logfile : '',s)") . read (5,'(a)') tline open (file=tline, unit=LOGout, status="unknown") write (6,'(''Enter output PDBfile : '‘',$§)') 55 read (5,'(a)') tline
K open (file=tline, unit=PDBout, status="unknown") c c...Main loop c 60 50 read (LISTin,'(a)',end=999) full name if (full_name(1:1).eq.'#') goto 50 if (parse_filename (full name, file path, file_name, file root, file ext)) continue BN len name = index (file_root,' ') - 1
Cc if (.not. readPDBFile (full name, data_handle)) then write(6, '{2X, '‘'**Unable to read PDB file'')') go to 100 end if c ¢...Select only fragments containing cysteines. ‘ c if (selectResByFilter(data_handle, Framelndex, FragmentFilter, numHitRes, HitResList)) continue if (numHitRes .eq. 0) goto 100 «¢ c...Get list of cysteines participating in disulfide bonds.
Cc call find _disulfide_pairs(data_handle, Framelndex, MAX RES, numSS, . SS_1, SS_2) if (numSS .eq. 0) goto 100 c c...Loop through fragments. Test whether: (a) cys_idx'th residue is participating in a disulfide and c (b) whether the fragment has an acceptable RMS overlap with the template coordinates. c do 90, icnt = 1, numHitRes icys = HitResList{icnt) + cys_idx - 1 jcys = 0 do jecnt = 1, numSS if (SS_1(jcnt).eq.icys) then jcys = SS_2(jcnt) else if (SS_2(jcnt).eq.icys) then jecys = SS_1{(jcnt) end if end do if (jcys .eq. 0) goto 90 c ¢...Extract coordinates for RMS test 40 ¢ numFragAtom = 0 do jent = 1, numTemplateRes jres = HitResList({icnt) + jcnt - 1 if (.not.getAtomOfRes (data_handle, Framelndex, jres, 'N', 45 AtomRec)) then write (6,'(''ERROR: Unable to get N of fragment residue v1,i4)') jres goto 90 else 50 numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index end if . if (.not.getAtomOfRes (data handle, FrameIndex, jres, 'CA',
AtomRec)) then 55 write (6,'(''ERROR: Unable to get CA of fragment residue : '',i4)') jres goto 90 else numFragAtom = numFragAtom + 1 60 FragAtomList (numFragAtom) = AtomRec.index end if if (.not.getAtomOfRes{data_handle, Framelndex, jres, 'C',
AtomRec)) then write (6,'(''ERROR: Unable to get C of fragment residue '1,i4)') Jjres goto 90 " else numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index
R end if if (.not.getAtomOfRes (data_handle, FrameIndex, jres, 'O',
AtomRec)) then write (6,'(''ERROR: Unable to get 0 of fragment residue '',1i4)') jres goto 90 else numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index end if do iatom = 1, numFragAtom jatom = FragAtomList (iatom) if (.not.getAtomData(data_handle, FrameIndex, jatom,
AtomRec)) then write (6,'(''ERROR: Unable to get record for fragment atom '’',i6})') jatom goto 90 else
FragmentVecArray(iatom) = AtomRec.vector end if end do end do
Cc c...RMS Fit to template. c call RMS_FIT(numTemplateVec, TemplateVecArray, FragmentVecArray,
RMS_WT, RMS_VALUE, tl, t2, r2) t2.x = -1.0 * t2.x t2.y = -1.0 * t2.y t2.z2 = -1.0 * £2.2 if (RMS_VALUE .gt. RMS_cutoff) goto 90 40 c c...Extract remaining atoms for fragment. c if (.not.getAtomOfRes (data_handle, FrameIndex, icys, 'CB’,
AtomRec)) then 45 write (6,'(''ERROR: Unable to get CB of fragment residue t1,14)') icys goto 90 else numFragAtom = numFragAtom + 1 50 FragAtomList (numFragAtom) = AtomRec. index end if , if (.not.getAtomOfRes (data_handle, FramelIndex, icys, 'SG',
AtomRec)) then write (6,' (''ERROR: Unable to get CB of fragment residue . 55 v1,i4)') icys goto 90 else numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index 60 end if if (.not.getAtomOfRes(data_handle, FrameIndex, jcys, 'CA',
AtomRec)) then write (6,'(''ERROR: Unable to get CA of fragment residue 'r,14)') Jeys goto 90 else numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index end if if (.not.getAtomOfRes (data_handle, Framelndex, jcys, 'CB', )
AtomRec)) then write (6,' (''ERROR: Unable to get CB of fragment residue troi4)') jeys goto 950 else numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index end if if (.not.getAtomOfRes(data_handle, FrameIlndex, jcys, 'SG',
AtomRec)) then write (6,'(''ERROR: Unable to get CB of fragment residue ',14)') jcys goto 90 else numFragAtom = numFragAtom + 1
FragAtomList (numFragAtom) = AtomRec.index end if call index_int_array (numFragAtom, FragAtomList, FragAtomIndex) call reorder_int_array (numFragAtom, FragAtomList, FragAtomIndex) ¢ c...Construct fragment object and apply transformations. c if (getResData(data_handle, 1, icys, ResRec)) continue if (ResRec.ChainID.ne.' '} then first _resnumber = ResRec.ChainID //
ResRec.residue_number (1:6) else first_resnumber = ResRec.residue_number (1:6) end if 40 full_structure_name = file_root (1l:len_name)//'_'//first_resnumber c if (make_trj_from_atom_list (data_handle, INT ONE, INT_ONE, numFragAtom, FragAtomlList, 45 . fragment_handle)) continue call rsm_translate_frame(fragment_handle, INT_ONE, t2) call rsm_rotate_frame (fragment_handle, INT_ONE, r2) call rsm_translate_frame(fragment_handle, INT_ONE, tl) call append fragment (fragment handle, full_structure_ name, 50 PDBout, .FALSE.) write (LOGout,'(a22,1x,£5.2)*') full_structure_name, RMS_value if (returnTrajectory (fragment _handle)) continue ‘ c 90 end do 55 100 if (returnTrajectory(data_handle)) continue goto 50 999 close (LISTin) close (PDBout) close (LOGout) 60 call exit end
EXAMPLE 2 ‘ Interleukin-2 (IL-2) (accession number SWS P01585) is a cytokine with a predominant role in the proliferation of activated T helper lymphocytes. Mitogenic stimuli or interaction of the T cell - receptor complex with antigen/MHC complexes on antigen presenting cells causes synthesis and secretion of IL-2 by the activated T cell, followed by clonal expansion of the antigen-specific cells.
These effects are known as autocrine effects. In addition, IL-2 can have paracrine effects on the growth and activity of B cells and natural killer (NK) cells. These outcomes are initiated by interaction of IL-2 with its receptor on the T cell surface. Disruption of the IL-2/1L-2R interaction can suppress immune function, which has a number of clinical indications, including graft vs. host disease (GVHD), transplant rejection, and autoimmune disorders such as psoriasis, uveitis, rheumatoid arthritis, and multiple sclerosis. There is structural information available of the C125A mutant [3INK, Mc Kay, D. B. & Brandhuber, B. J., Science 257: 412 (1992)].
Cloning of Human IL-2
Numbering of the wild type and mutant IL-2 residues follows the convention of the first amino acid residue (A) of the mature protein being residue number 1 independent of any presequence e.g. met for the E. coli produced protein [see Taniguchi, T., et al., Nature 302: 305-310 (1983) and Devos,
R, etal, Nucleic Acids Res. 11: 4307-4323 (1983)].
The DNA sequence encoding human Interleukin-2 (IL-2) was isolated from plasmid pTCGF-11 (ATCC). PCR primers were designed to contain restriction endonuclease sites Ndel and Xhol for subcloning into a pRSET expression vector (Invitrogen).
IL2 GGAATTCCATATGGCACCTACTTCARGTTCTACARAGAARACA SEQ ID NO:1
Forward 1.2 CCGCTCGAGTCAAGTTAGTGTTGAGATGATGCTTTGACA SEQ ID NO:2
Reverse
Double-stranded IL-2/pRSET was prepared by the following procedure. The PCR product 3 containing the IL-2 sequence and pRSET were both cut with restriction endonucleases (1 pl PCR product, 1 ul each endonuclease, 2 pM appropriate 10x buffer, 15 pl water; incubated at 37 C for 2 3 30 hours). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TAE buffer) and ligated together using T4 DNA ligase (80 ng IL-2 sequence, 160 ng pRSET vector, 4 pl 5X ligase buffer (300 mM Tris pH 7.5, 50 mM MgCl,, 20% PEG 8000, 5 mM ATP, 5 mM DTT), 1 ul ligase; incubated at 15 C for 1 hour). 10 ul of the ligase reaction mixture was transformed into
XL1 blue cells (Stratagene) (10 pl reaction mixture, 10 pl 5X KCM [0.5 M KCI, 0.15 M CaCl,, 0.25 M MgCl], 30 pl water, 50 ul PEG-DMSO competent cells; incubated at 4 C for 20 minutes, 25 C for 10 minutes), and plated onto LB/agar plates contaming 100 pg/ml ampicillin. After incubation at 37 C overnight, single colonies were grown in S m! 2YT media for 18 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA miniprep kit. :
Generation of IL-2 Cys Mutations
Site-directed mutants of IL-2 were prepared by the single-stranded DNA method (modification of
Kunkel, T. A., Proc. Natl. Acad. Sci. U. S. A. 83: 488-492 (1985). Oligonucleotides were designed to contain the desired mutations and 15-20 bases of flanking sequence.
The single-stranded form of the IL-2/pRSET plasmid was prepared by transformation of double- stranded plasmid into the CJ236 cell line (1 pl IL-2/pRSET double-stranded DNA, 2 pl 2x KCM salts, 7 ul water, 10 pl PEG-DMSO competent CJ236 cells; incubated at 4 C for 20 minutes and 25
C for 10 minutes; plated on LB/agar with 100 pg/ml ampicillin and incubated at 37 C overnight).
Single colonies of CJ236 cells were then grown in 50 ml 2YT media to midlog phase; 5 ul VCS helper phage (Stratagene) were then added and the mixture incubated at 37 C overnight. Single- stranded DNA was isolated from the supernatant by precipitation of phage (1/5 volume 20% PEG 8000/2.5 M NaCl; centrifuge at 12K for 15 minutes.). Single-stranded DNA was then isolated from phage using Qiagen single-stranded DNA kit. Sequencing identified a leucine-25 to serine mutation, which was corrected by mutagenesis using the “S25L" oligonucleotide.
S25L TAATTCCATTCAAAATCATCTGTA SEQ ID NO:3
Mutagenic Oligonucleotides
N30C GGTGAGTTTGGGATTCTTGTAACAATTAATTCCATTCAAAATCATCTG SEQ ID NO:4
Y3IC GGTGAGTTTGGGATTCTTACAATTATTAATTCCATTC SEQ ID NO:5
K32C GGTGAGTTTGGGATTACAGTAATTATTAATTCC SEQ ID NO:6
N33C CCTGGTGAGTTTGGGACACTTGTAATTATTAATTCC SEQ ID NO:7
K35C GCATCCTGGTGAGACAGGGATTCTTGTAATTATTAATTCC SEQ ID NO:8
R38C CTTAAATGTGAGCATACAGGTGAGTTTGGGATTC SEQ ID NO:9
F42C GGGCATGTAAAACTTACATGTGAGCATCCTGG SEQ ID NO: 10
K43C CTTGGGCATGTAAAAACAAAATGTGAGCATCC SEQ ID NO:11
Y45C GGCCTTCTTGGGCATACAAAACTTAAATGTGAGC SEQ ID NO:12 ; E68C CTCAAACCTCTGGAGTGTGTGCTAAATTTAGC SEQ ID NO:13
L72C GTTTTTGCTTTGAGCACAATTTAGCACTTCCTCC SEQ ID NO:14
N77C CCTGGGTCTTAAGTGAAAACATTTGCTTTGAGCTAAATTTAGC SEQ ID NO:15
Y31C K43C
GGGCATGTAAAAACAARATGTGAGCATCCTGGTGAGTTTGGGATTCTTACAATTATTAATTCC
SEQ ID NO:16
There was an additional double mutant made, L72C K43C, using the oligonucleotides corresponding to K43C and L72C single mutants (SEQ ID NO:11 and SEQ ID NO:14 respectively).
Site-directed mutagenesis was accomplished as follows: Mutagenesis oligonucleotides were dissolved to a concentration of 10 OD and phosphorylated on the 5° end (2 pl oligonucleotide, 2 ul 10 mM ATP, 2 ul 10X Tris-magnesium chloride buffer, 1 pl 100 mM DTT, 10 pl water, 1 pl T4
PNK; incubate at 37 C for 45 minutes.). Phosphorylated oligonucleotides were then annealed to single-stranded DNA template (2 pl single-stranded plasmid, 1 pl oligonucleotide, 1 ul 10x TM buffer, 6 ul water; heat at 94 C for 2 minutes, 50 C for 5 minutes, cool to room temperature).
Double-stranded DNA was then prepared from the annealed oligonucleotide/template (add 2 pl 10X
TM buffer, 2 pl 2.5 mM dNTPs, 1 pl 100 mM DTT, 1.5 ul 10 mM ATP, 4 pl water, 0.4 ul T7 DNA polymerase, 0.6 pl T4 DNA ligase; incubate at room temperature for 2 hours). E. coli (XL1 blue,
Stratagene) was then transformed with the double-stranded DNA (1 pl double-stranded DNA, 10 ul 5x KCM, 40 pl water, S50 pl DMSO competent cells; incubate 20 minutes at 4 C, 10 minutes at room temperature), plated onto LB/agar containing 100 pg/ml ampicillin, and incubated at 37 C overnight. Approximately four colonies from each plate were used to inoculate 5 ml 2YT containing 100 pg/ml ampicillin; these cultures were grown at 37 C for 18-24 hours. Plasmids were then isolated from the cultures using Qiagen miniprep kit. These plasmids were sequenced to i determine which IL-2/pRSET clones contained the desired mutation. « Sequencing primers
Forward primer, “T7” AATACGACTCACTATAG SEQ ID NO:17
Reverse primer, “RSET TAGTTATTGCTCAGCGGTGG SEQ ID NO:18
REV”
Expression of IL-2 Mutants
Mutant proteins were expressed as follows: IL-2/pRSET clones containing the mutation were transformed into BL21 DE3 pLysS cells (Invitrogen) (1 ul double-stranded DNA, 2 ul $x KCM. 7 ul water, 10 pul DMSO competent cells; incubate 20 minutes at 4 CC, 10 minutes at room temperature), plated onto LB/agar containing 100 pg/ml! ampicillin, and incubated at 37 C overnight. 10 ml cultures in 10 ml 2YT with 100 pg/ml ampicillin were grown overnight from single colonies. 100 ml 2YT/ampicillin (100 pg/ml) was inoculated with these overnight cultures and incubated at 37 C for 3 hours. This culture was then added to 1.5 L 2YT/ampicillin (100 pg/ml) and incubated until late-log phase (absorbance at 600 nm ~0.8), at which time IPTG was added to a final concentration of 1 mM. Cultures were incubated at 37 C for another 3 hours and then cells were pelleted (10 Krpm, 10 minutes) and frozen at -20 C overnight.
IL-2 mutants were then purified from the frozen cell pellets. First, cells were lysed in a microfluidizer (100 mi Tris EDTA buffer, 3 passes through a Microfluidizer {Microfluidics 110S]) and inclusion bodies were isolated by precipitation (10 Krpm, 10 minutes). Following cell lysis, 50 pl of cell material was saved for analysis by SDS-PAGE. All mutants expressed as determined by gel but several (e.g. E68C) precipitated on refolding. Inclusion bodies were then resuspended in 45 mi guanidine HCl and spun at 10 Krpm for 10 minutes. The supernatant was added to refolding buffer (45 ml guanidine HCl, 36 ml Tris pH 8, 231 mg cysteamine, 46 mg cystamine, 234 ml water) and incubated at room temperature for 3-5 hours. The mixture was then spun at 10 Krpm for 20 minutes. and the supernatant dialyzed 4-5 times in 5 volumes of buffer (10 mM ammonium acetate pH 6, 25 mM NaCl). The protein solution was then filtered through cellulose and injected onto an
S Sepharose fast flow column (2.5 cm diameter x 14 cm long) at 5 ml/min. The protein was then eluted using a gradient of 0 — 75% Buffer B over 60 minutes (Buffer A: 25 mM NH,OAc, pH 6, 25 mM NaCl; Buffer B: 25 mM NH,OAc, pH 6, | M NaCl). Purified protein was then exchanged into the appropriate buffer for the TETHER assay (typically 100 mM Hepes, pH 7.4). Average yields were 0.5 to 4 mg/L culture.
EXAMPLE 3
CLONING AND MUTAGENESIS OF HUMAN IL-4 .
IL-4 (accession number SWS P05112) is a cytokine that is critical for early immune response and allergic response; its interaction with the IL-4R is involved in the generation of Th2 cells. IL-4 , recruits and activates B-cells that produce IgE (immunoglobulin E), eosinophils, and mast cells.
These cells in turn tag and attack parasites in skin and in mucosal tissues and eject them from these tissues. The role of the IL-4/IL4R interaction in immune and allergic responses suggests that disruption of this interaction may alleviate such conditions as asthma, dermatitis, conjunctivitis, and rhinitis. There are crystal structures of IL-4 in isolation and in co-complex with a receptor molecule [1HIK, Muller, T. & Buehner, M., J Mol Biol 247: 360-372 (1995); with receptor alpha, 11AR, Hage, T., et al, Cell 97: 271-281 (1999)].
Cloning of human IL-4 ’ Numbering of the wild type and mutant IL-4 residues follows the convention of the first amino acid residue (H) of the mature protein being residue number 1 independent of any presequence e.g. met for the E. coli produced protein [Yokota, T., et al., Proc. Natl. Acad. Sci. U. S. A. 83: 5894-5898 (1986)]. IL-4 lacking the secretion signal and containing an additional N-terminal methionine was expressed intracellularly in E. coli from the Sunesis RSET.IL4 plasmid.
The DNA sequence encoding human interleukin-4 (IL4) was isolated by PCR from the plasmid pcD-hIL-4 (ATCC Accession No. 57592) using PCR primers:
IL4 ForRse 5° GGGTTTCATATGCACAAGTGCGATATCACCTT SEQ ID NO:19
IL4 RevRse 5° CCGCTCGAGTCAGCTCGAACACTTTGAATA SEQ ID NO:20
These primers correspond to extracellular domain of the protein and which were designed to contain restriction endonuclease sites Nde I and Xhol for subcloning into a pRSET vector (Invitrogen). The PCR reaction was purified on a Qiaquick PCR purification column (Qiagen).
The PCR product containing the IL4 sequence was cut with restriction endonucleases (41 ul PCR product, 2 pl each endonuclease, 5 ul appropriate 10x buffer; incubated at 37 C for 90 minutes).
The pRSET vector was cut with restriction endonucleases (6 ug DNA, 4 ul each endonuclease, 10 ul appropriate 10x buffer, water to 100 pl; incubated at 37 C for 2 hours; add 2 ul CIP and incubated at 37 C for 45 minutes). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TBE buffer) and ligated together using T4 DNA ligase (200 ng pRSET vector, 150 ng IL4 PCR product, 4 pl 5x ligase buffer {300 mM Tris pH 7.5, 50 mM MgCl, 20%
PEG 8000, 5 mM ATP, 5 mM DTT], 1 ul ligase; incubated at 15 C for 1 hour). 10ul of the ligation reaction was transformed into XL1 blue cells (Stratagene) (10 pl reaction mixture, 10 pl 5x KCM
RX [0.5 M KCl, 0.15 M CaCl,, 0.25 M MgCl], 30 pl water, 50 ul PEG-DMSO competent cells; incubated at 4 C for 20 minutes, 25 C for 10 minutes), and plated onto LB/agar plates containing ] 30 100 pg/ml ampicillin. After incubation at 37 C overnight, single colonies were grown in 3 ml 2YT media for 18 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA miniprep kit.
Generation of IL-4 Cysteine Mutations
Mutations were generated using as previously described [Kunkel, T. A, et al., Methods_Enzymol. 154:367-82 (1987)]. DNA oligonucleotides used are shown below and were designed to hybridize with sense strand DNA from plasmid. Sequences were verified using primers with SEQ ID NO:17 and SEQ ID NO:18.
Mutagenic Oligonucleotides
Q8C TTGATGATCTCACATAAGGTGA SEQ ID NO:21
EOC AGTTTTGATGATACACTGTAAGGTGAT SEQ ID NO:22
K12C GCTGTTCAAAGTGCAGATGATCTCCTG SEQ ID NO:23
S16C CTGCTCTGTGAGGCAGTTCARAGT SEQ ID NO:24
K37C CAGTTGTGTTACAGGAGGCAGCAAAG SEQ ID NO:25
N38C CCTTCTCAGTTGTGCACTTGGAGGC SEQ ID NO:26
K42C GCAGAAGGTTTCACACTCAGTTGTG SEQ ID NO:27
Q54C GGCTGTAGAAACACCGGAGCACAGTCG SEQ ID NO:28
Q78C GAATCGGATCAGACACTTGTGCCTGTG SEQ ID NO:29
R8IC GCCGTTTCAGGAAGCAGATCAGCTGC SEQ ID NO:30
R85C CCTGTCGAGACATTTCAGGAATCG SEQ ID NO:31
R8S8C CCCAGAGGTTGCAGTCGAGCCG SEQ ID NO:32
N89C CCCAGAGGCACCTGTCGAGCCG SEQ ID NO:33
N97C CACAGGACAGGAACACAAGCCCGCC SEQ ID NO:34
K102C CTGGTTGGCTTCACACACAGGACAGG SEQ ID NO:35
K117C CTCTCATGATCGTGCATAGCCTTTCC SEQ ID NO:36
RI21C GAATATTTCTCACACATGATCGTC SEQ ID NO:37
Expression of 11-4 Mutants BL21 DE3 cells (Stratagene) were transformed with RSET.IL4 plasmids containing the described cysteine mutations and plated onto LB agar containing 100 pg/ml ampicillin. After overnight 28
BE CL growth fresh individual colonies were used to inoculate a 37 C overnight shake flask culture with 30 ml 2YT (with 50 pg/ml ampicillin) media. In the moming this overnight culture was used to inoculate 1.5 L of 2YT/ampicillin (50 pg/ml), which was further cultured at 37 C and 200 rpm in a . 4.0 L dented bottom shake flask. When the optical density of the culture at A = 600 reached 0.8 it was induced to produce IL-4 protein by the addition of 1 mM IPTG. After 4 more hours of ‘ incubation the cultures were harvested, the cells pelleted by centrifugation at 7K rpm for 10 minutes (K-9 Komposite Rotor), and frozen at 20 C.
The cell pellet was then thawed and resuspended in 100 ml of 10 mM Tris pH 8, 50 mM NaCl and 1 mM EDTA. This solution was kept chilled and run through a microfluidizer twice (model 110S
Microfluidics Corp, Newton Massachusetts), and centrifuged at 7K rpm for 15 minutes). The pellet containing the IL-4 inclusion bodies was then resuspended in a 50 ml solution of 5 M guanidine
HCl, 50 mM Tris pH 8, 50 mM NaCl, 2.5 mM reduced glutathione, and 0.25 mM oxidized glutathione, and incubated for one hour at room temperature with gentle mixing. The solubilized protein solution was then centrifuged at 7.5K rpm for 15 minutes and the supernatant 0.45 um filtered to remove insoluble debris.
The IL-4 was refolded by slowly adding the filtered solution to 9 volumes (450 ml) of 50 mM Tris pH 8, 50 mM NaCl, 2.5 mM reduced glutathione and 0.25 mM oxidized glutathione over a 30 minute period. The resulting solution was further incubated with slow stirring for 3 hours at room temperature, then placed in a 3000 mwco dialysis bag and exchanged 3 times against 20 L of 0.5x
PBS (phosphate-buffered saline).
The refolded mutant proteins were then purified using a Hi-S Column Cartridge (Bio-Rad). After clarifying the protein solution by centrifugation and filtration it was loaded onto the column at a § ml/min flow rate. The column was next washed with buffer A (0.5x PBS) for 15-20 minutes, and 1.5 minute 7.5 ml fractions were collected over a 0-100% gradient between Buffer A and Buffer B (PBS, 1M NaCl). The fractions that contained the IL-4 protein as determined by SDS-PAGE and optical density as 280 nm were pooled, concentrated with a 5K mwco filter, and their buffer exchanged to PBS. This solution was then 0.2 um filtered, frozen in ethanol dry ice bath, and . stored at : -80 C.
EXAMPLE 4
CLONING AND MUTAGENESIS OF HUMAN TUMOR NECROSIS FACTOR-AILPHA ( INE- a)
Tumor necrosis factor-a (TNF-a) (accession number SWS P01375) is a cytokine produced mainly by activated macrophages, and it plays a critical role in immune responses including septic shock, inflammation, and cachexia. This protein can interact with two receptors, TNF R1 and TNF R2.
These two receptors share no similarity in their intracellular domains, which suggests that they are involved in different signal transduction pathways. A structure of TNF-a is available [1TNF. Eck.
M. J. et al., J Biol Chem 264: 17595-17605(1989)]; TNF-a is an elongated beta sheet, and it forms a trimer. Mutation of some of the intersubunit residues of the trimer indicates that they form part of the binding site to the receptor. However, there is no structure of TNF bound to a receptor to date.
Cloning of human TNF-a
The DNA sequence encoding human Tumor Necrosis Factor (TNF) was isolated by PCR from the plasmid pUC-RI-dlarge (ATCC #65947) using PCR primers listed below corresponding to extracellular domain of the protein and which were designed to contain restriction endonuclease sites Nde I and Xhol for subcloning into a pRSET vector (Invitrogen).
TNF RSET For GGGTTTCATATGGTCCGTTCATCTTCTCGAAC SEQ ID NO:38 5
TNF RSET Rev ~~ CCGCTCGAGTCACAGGGCAATGATCCCAA SEQ ID NO:39 5
The PCR reaction was purified on a Qiaquick PCR purification column (Qiagen). The PCR product containing the TNF sequence was cut with restriction endonucleases (41 pl PCR product, 2 ul each endonuclease, 5 ul appropriate 10x buffer; incubated at 37 C for 90 minutes). The pRSET vector was cut with restriction endonucleases (6 pg DNA, 4 pl each endonuclease, 10 pl appropriate 10x buffer, water to 100 pl; incubated at 37 C for 2 hours; added 2 ul CIP and incubated at 37 C for 45 minutes). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TBE buffer) and ligated together using T4 DNA ligase (200 ng pRSET vector, 150 ng TNF PCR product, 4 ul 5x ligase buffer [300 mM Tris pH 7.5, 50 mM MgCl, 20% PEG 8000, 5S mM ATP, 5 mM
DTT], 1 pl ligase; incubated at 15 C for 1 hour). 10 pl of the ligation reaction was transformed into XL1 blue cells (Stratagene) (10 ul reaction mixture, 10 ul 5x KCM [0.5 M KCl, 0.15 M CaCl,, 0.25 M MgCl,], 30 pl water, 50 ul PEG-DMSO competent cells; incubated at 4 C for 20 minutes, 25 C for 10 minutes), and plated onto LB/agar plates containing 100 pg/ml ampicillin. After . incubation at 37 C overnight, single colonies were grown in 3 ml 2YT media for 18 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA . ' miniprep kit. Sequencing of TNF genes was accomplished using primers having SEQ ID NO:17 and SEQ ID NO:18.
Generation of TNF-a Cysteine Mutations
Mutations were generated using as previously described {Kunkel, T. A., et al., Methods_Enzymol. 154: 367-82 (1987)]. DNA oligonucleotides used are shown below and were designed to hybridize with sense strand DNA from plasmid. Sequences of the mutants were verified using primers with
SEQID NO:17 and SEQ ID NO:18.
Mutagenic Oligonucleotides
R32C GAGGGCATTGGCGCAGCGGTTCAGCCAC SEQ ID NO:40
A33C CAGGAGGGCATTGCACCGGCGGTTCAG SEQ ID NO:41
N34C GGCCAGGAGGGCACAGGCCCGGCGGTTC SEQ ID NO:42
R44C CAGCTGGTTATCACACAGCTCCACGCC SEQ ID NO:43
Q47C TGGCACCACCAGGCAGTTATCTCTCAG SEQ ID NO:44
T72C GAGGAGCACATGGCAGGAGGGGCAGCC SEQ ID NO:45
H73C GGTGAGGAGCACACAGGTGGAGGGGCAG SEQ ID NO:46
L75C GGTGTGGGTGAGGCACACATGGGTGGAG SEQ ID NO:47
T77C GCTGATGGTGTGGCAGAGGAGCACATG SEQ ID NO:48
V91C CAGAGAGGAGGTTGCACTTGGTCTGGTAG SEQ ID NO:49
NO2C GGCAGAGAGGAGGCAGACCTTGGTCTG SEQ ID NO:50
S95C GCTCTTGATGGCACAGAGGAGGTTGAC SEQ ID NO:51
E104C CCTCAGCCCCCTCTGGGGTGCACCTCTGGCAGGGG SEQ ID NO:52
T105C CCTCAGCCCCCTCTGGGCACTCCCTCTGGCAGGGG SEQ ID NO:53
E107C GGCCTCAGCCCCGCATGGGGTCTCCCTCTGGC SEQ ID NO:54
El10C CCAGGGCTTGGCGCAAGCCCCCTCTGGGG SEQ ID NO:55
All1C ATACCAGGGCTTGCACTCAGCCCCCTC SEQ ID NO:56 : K112C GGGTAGTTTCTGGCAAAATATGGCTTG SEQ ID NO:57
Q125C CACCCTTCTCCAGGCAGAAGACCCCTCC SEQ ID NO:58
R138C GCTGAGATCAATTGTCCCGACTATCTC SEQ ID NO:59
E146C GACCTGCCCAGAGCAGGCAAAGTCGAG SEQ ID NO:60 5147C GTAGACCTGCCCACACTCGGCAAAGTC SEQ ID NO:61
Expression of TNF-a Mutant Proteins
BL21 DE3 cells (Stratagene) were transformed with RSET TNF-a plasmids containing the described cysteine mutations and plated onto LB agar containing 100 pg/ml ampicillin. After ovemnight growth fresh individual colonies were used to inoculate a 37 C overnight shake flask culture with 30 ml 2YT (with 50 pg/ml ampicillin) media. In the morning this overnight culture was used to inoculate 1.5 L of 2YT/ampicillin (50 pg/ml), which was further cultured at 37 C and 200 rpm in a 4.0 L dented bottom shake flask. When the optical density of the culture at A = 550 reached 0.8 it was induced to produce TNF-a protein by the addition of 1 mM IPTG. After 4 more hours of incubation the cultures were harvested, the cells pelleted by centrifugation at 7K rpm for 10 minutes (K-9 Komposite Rotor), and frozen at -20 C.
The cell pellet was then thawed and resuspended in 100 m}! of 25 mM ammonium acetate pH 6, 1 mM DTT and 1 mM EDTA. This solution was kept chilled and run through a microfluidizer twice (model 1108 Microfluidics Corp, Newton Massachusetts), centrifuged at 9K rpm for 15 minutes to remove insoluble material and further clarified by 0.45 um filtration. This solution was then loaded onto an S-Sepharose ff Column (Bio-Rad) column at a 5 ml/min flow rate. The flow rate was then increased to 7.5 mL/min for the following steps. The column was next washed with Buffer A (0.2
M ammonium acetate pH 6, 1 mM DTT) until the OD, approached zero (15-20 minutes), and fractions were collected over a 0-100% gradient in 60 minutes between Buffer A and Buffer B (1 M ammonium acetate pH 6, 1 mM DTT). The fractions that contained the TNF-a protein as determined by SDS-PAGE and optical density at 280 nm were pooled and placed in a 3000 mwco dialysis bag and dialyzed overnight at 4 C against 4 L of 10 mM Tris pH 7.5, 10 mM NaCl, and 1 mM DTT. The dialyzed protein solution was then clarified by centrifuging at 13.5K rpm for 10 minutes filtering through a 0.2 pum filter.
The mutant proteins were then loaded onto a Q-Sepharose Column (Bio-Rad) at a 5 ml/min flow : rate. The flow rate was increased to 7.5 mL/min for the following steps. The column was next washed with Buffer A (10 mM Tris pH 7.5, 10 mM NaCl, 1 mM DTT) until the ODay approached zero (15-20 minutes), and fractions were collected over a 0-100% gradient in 40 minutes between
Buffer A and Buffer B (10 mM Tris pH 7.5, 0.5 M NaCl, 1 mM DTT). The fractions that contained the TNF-a protein as determined by SDS-PAGE and optical density at 280 nm were pooled and concentrated with a SK mweco filter, and their buffer exchanged to PBS. This solution was then 0.2 um filtered, frozen in ethanol dry ice bath, and stored at —80 C. . EXAMPLE §
Binding of the IL-1 receptor (accession number SWS P14778) to IL-1alpha or IL-1beta is another important mediator of immune and inflammatory responses. This interaction is controlled by at least three mechanisms. Firstly, the protein IL-R2 binds to IL-1alpha and IL-1beta but does not signal. Secondly, proteolytically processed IL-1R1 and IL-1R2 are soluble and bind to IL-1 in circulation. Finally there exists a natural IL-1R antagonist called IL-1ra, that functions by binding
IL-1R1 and thereby blocking IL-1R1 binding of IL-lalpha and IL-lbeta. Inhibition of these teractions with an orally available small molecule would be desirable in treatment of diseases such as rheumatoid arthritis, autoimmune disorders, and ischemia. Two structures of IL-1R have been solved [with a antagonist peptide, 1G0Y, Vigers, G. P. A, et al., J. Biol. Chem. 275:36927- 36933 (2000); with receptor antagonist, 1IRA, Schreuder, H., et al., Nature 386: 194-200 (1997)).
Cloning of human IL-1 receptor type I
The IL-1 receptor has three regions: an N-terminal extracellular region, a transmembrane region, and a C-terminal cytoplasmic region. The extracellular region itself contains three immunoglobin- like C2-type domains. The constructs used here contain the two N-terminal domains of the extracellular region. Numbering of the wild type and mutant IL1R residues follows the convention of the first amino acid residue (L) of the mature protein being residue number 1 after processing of the signal sequence [Sims, J. E., et al, Proc. Natl. Acad. Sci. U. S. A. 86: 8946-8950 (1989)]. The sequence of the 2 domain protein is shown below as SEQ ID NO:62. 1 LEADKCKERE EKIILVSSAN EIDVRPCPLN PNEHKGTITW YKDDSKTPVS TEQASRIHOH 61 KEKLWFVPAK VEDSGHYYCV VRNSSYCLRI KISAKFVENE PNLCYNAQAI FKQKLPVAGD 121 GGLVCPYMEF FKNENNELPK LQWYKDCKPL LLDNIHFSGV KDRLIVMNVA EKHRGNYTCH 181 ASYTYLGKQY PITRVIEFIT LEENK
In brief, cysteine mutants were made in the context of a 2 domain receptor and a 2 domain receptor with a his tag. In addition, the constructs possessed a mutation at a glycosylation site, and one construct possessed a mutation at a glycosylation site in addition to a deletion at the C-terminal residue of the 2 domain region. The assembly of these constructs is described below. ’ The DNA sequence encoding human Interleukin-1 receptor (IL1R) was isolated by PCR from a
HepG2 cDNA library (ATCC) using PCR primers (IL1RsigintFor 5°; IL1RintRev 5”) corresponding to the signal sequence and the end of the extracellular domain of the protein.
IL1RsigintFor TTACTCAGACTTATTTGTTTCATAGCTCTA SEQ ID NO:63
IL1RintRev GAAATTAGTGACTGGATATATTAACTGGAT SEQ ID NO:64
The appropriate sized band was isolated from an agarose gel and used as the template for a second round of PCR using oligos (IL1RsigFor; ILIR319Rev), which were designed to contain restriction endonuclease sites EcoRI and Xhol for subcloning into a pFBHT vector.
IL1Rsig For CCGGAATTCATGAAAGTGTTACTCAGACTTATTTGTTTC SEQ ID
NO:65
ILIR319 Rev ~~ CCGCTCGAGTCACTTCTGGAAATTAGTGACTGGATATATTAA SEQ ID
NO:66
The pFBHT vector is modified from the original pFastBacl(Gibco/BRL) by cloning the sequence for TEV protease followed by (His), tag and a stop signal into the Xhol and HinDIII sites. The
PCR product containing the IL1R sequence was cut with restriction endonucleases (41 pl PCR product, 2 ul each endonuclease, 5 ul appropriate 10x buffer; incubated at 37 C for 90 minutes).
The pFBHT vector was cut with restriction endonucleases (6 ug DNA, 4 ul each endonuclease, 10 ul appropriate 10x buffer, water to 100 pl; incubated at 37 C for 2 hours; add 2 pl CIP and incubated at 37 C for 45 minutes). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TBE buffer) and ligated together using T4 DNA ligase (200 ng pFBHT vector, 150 ng IL1R PCR product, 4 nl 5x ligase buffer [300 mM Tris pH 7.5, 50 mM MgCl, 20%
PEG 8000, 5 mM ATP, 5 mM DTT], 1 pl ligase; incubated at 15 C for 1 hour). 10 ul of the ligation reaction was transformed into XL1 blue cells (Stratagene) (10 pl reaction mixture, 10 pl 5x
KCM [0.5 M KC], 0.15 M CaCl,, 0.25 M MgCl,], 30 ul water, 50 ul PEG-DMSO competent cells; incubated at 4 C for 20 minutes, 25 C for 10 minutes), and plated onto LB/agar plates containing 100 pg/ml ampicillin. After incubation at 37 C overnight, single colonies were grown in 3 ml 2YT media for 18 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA miniprep kit.
A 2-domain version of ILIR was created by PCR using the 3-domain IL1IR-FBHT clone as a template. PCR was performed using the primers IL1RsigFor (SEQ ID NO:65) corresponding to the signal sequence, in addition to one of the following two reverse primers. The reverse primers are
IL1R2Drevstop-Xho, which corresponds to the end of the second extracellular domain of the protein with a stop signal, and JL1R2Drev-Xho, which corresponds to the end of the second extracellular domain of the protein without a stop signal to create a fusion with the TEV protease site and the His tag.
IL1R2Drevstop-Xho CCGCTCGAGTCATCATTTGTTTTCCTCTAGAGTAATARA SEQ ID ) NO:67
IL1R2Drev-Xho CCGCTCGAGTCATTTGTTTTCCTCTAGAGTAATAAA SEQ ID
NO:68
The PCR primers contain restrictions sites (EcoRI at the 5’end and Xhol at the 3’ end), which were used to ligate the 2-domain version into the pFBHT vector. The PCR product containing the
ILIR2D sequence was cut with restriction endonucleases (41 pul PCR product, 2 pl each endonuclease, 5 pl appropriate 10x buffer; incubated at 37 C for 90 minutes). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TBE buffer) and ligated together using T4 DNA ligase (200 ng pFBHT vector, 150 ng ILIR2D PCR product, 4 pl 5x ligase buffer [300 mM Tris pH 7.5, 50 mM MgCl,, 20% PEG 8000, 5 mM ATP, 5 mM DTT], 1 pl ligase; incubated at 15 C for 1 hour). 10 pl of the ligation reaction was transformed into XL1 blue cells (Stratagene) (10 pl reaction mixture, 10 pl Sx KCM [0.5 M KCl, 0.15 M CaCl,, 0.25 M MgCl,], 30 ul water, 50 ul PEG-DMSO competent cells; incubated at 4 C for 20 minutes, 25 C for 10 minutes), and plated onto LB/agar plates containing 100 pg/ml ampicillin. After incubation at 37
C overnight, single colonies were grown in 3 ml 2YT media for 18 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA miniprep kit.
Additionally, the two glycosylation sites within IL1R2D, N83 and N176, were each individually mutated to a histidine, in order to make a more homogeneous protein. Each of these single mutants were made in the context of the 2-domain protein without a his tag (sILIRd2-FB) and the 2-domain protein with a his tag (sILIRd2-FBHT). Mutation was accomplished by PCR using two sets of primers to make two fragments, followed by stitching together of the fragments using the outside primers IL1RsigFor (SEQ ID NO:65) and either ILIR2Drevstop-Xho (SEQ ID NO:67) or
ILIR2Drev-Xho (SEQ ID NO:68) as described below. Brief descriptions of the 2-domain glycosylation mutants and their construction follow. ) The construct for the N83H mutant without a his tag is referred to as sILIR2D-N83H-FB, and it was created using IL1RsigFor (SEQ ID NO:65) and N83HR (SEQ ID NO:69) along with N83HF (SEQID NO:70), and IL1R2Drevstop-Xho (SEQ ID NO:67)
N&3IHR GAGGCAGTAAGATGAATGTCTTACC SEQ ID NO:69
N&3HF CTATTGCGTGGTAARGACATTCATCTT SEQ ID NO:70
The construct for the N83H mutant with a his tag 1s referred to as sSILIR2D-N83H-FBHT and was created using IL1RsigFor (SEQ ID NO:65), and N83HR (SEQ ID NO:69) along with N83HF (SEQ
ID NO:70) and IL1R2Drev-Xho (SEQ ID NO:68).
The construct for the N176H mutant without a his tag is referred to as sSILIR2D-N176H-FB and it was created using IL1RsigFor (SEQ ID NO:65), N176HR (SEQ ID NO:71), N176HF (SEQ ID
NO:72), and IL1R2Drevstop-Xho (SEQ ID NO:67).
N176HR ATGACAAGTATAGTGCCCTCTATGCTTTTCACG SEQ ID NO:71
N176HF GCTGAAAAGCATAGAGGGCACTATACTTGTCAT SEQ ID NO:72
The construct for the N176H mutant with a his tag is referred to as sSILIR2D-N176H-FBHT.and it was created using IL1RsigFor (SEQ ID NO:65), and N176HR (SEQ ID NO:71), along with
N176HF (SEQ ID NO:72), and IL1R2Drev-Xho (SEQ ID NO:68).
The PCR products were isolated from and agarose gel and PCR was used to sew the two fragments together using the IL1RsigFor (SEQ ID NO:65) and IL1R2Drevstop-Xho (SEQ ID NO:67) or
IL1R2Drev-Xho primers (SEQ ID NO:68). The PCR products containing the IL1R2D sequences mutated at the glycosylation site were cut with restriction endonucleases (41 pul PCR product, 2 ul each endonuclease, 5 ul appropriate 10x buffer; incubated at 37 C for 90 minutes). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TBE buffer) and ligated together using T4 DNA ligase (200 ng pFBHT vector, 150 ng ILIR2D PCR product, 4 pl 5x ligase buffer [300 mM Tris pH 7.5, 50 mM MgCl,, 20% PEG 8000, 5 mM ATP, 5 mM DTT], 1 pl ligase; incubated at 15 C for 1 hour). 10 pl of the ligation reaction was transformed into XL1 blue cells (Stratagene) (10 pl reaction mixture, 10 pl 5x KCM {0.5 M KCl, 0.15 M CaCl, 0.25 M MgCl}, 30 pl water, 50 pl PEG-DMSO competent cells; incubated at 4 C for 20 minutes, 25 C for 10 \ minutes), and plated onto LB/agar plates containing 100 ug/ml ampicillin. After incubation at 37
C overnight, single colonies were grown in 3 ml 2YT media for 18 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA miniprep kit. The subsequent plasmids are referred to as sILIR2D-N83H-FB or sILIR2D-N83H-FBHT and as sILIR2D-N176H-FB or as sIL1R2D-N176H-FBHT.
Finally, an additional construct was made using the sIL1R2D-N83H-FB construct. The additional construct contains the 2-domain IL1R receptor without a his tag and with two mutations: a N83H glycosylation mutation and a deletion of the C-terminal residue (K205). This construct is named . sILIR2D2M-FB, and was made using the K205del oligonucleotide. . K205del CTCGAGTCATCAGTTTTCCTCTAG : SEQ ID NO:73
Generation of IL-1RI Cysteine Mutations
Site-directed mutants of ILIR2D were prepared by the single-stranded DNA method [modification of Kunkel, T. A., Proc. Natl. Acad. Sci. U. S. A. 82: 488-492 (1985)]. Oligonucleotides were designed to contain the desired mutations and 15-20 bases of flanking sequence.
The single-stranded form of the ILIR2D (sIL1R2D-FBHT, sIL1R2D-N176H-FB/FBHT, sIL1R2D-
N83H-FB/FBHT, sILIR2D2M-FB) plasmid was prepared by transformation of double-stranded plasmid into the CJ236 cell line (1 pul IL1IR-FB double-stranded DNA, 2 ul 2x KCM salts, 7 pl water, 10 pl PEG-DMSO competent CJ236 cells; incubated at 4 C for 20 minutes and 25 C for 10 minutes; plated on LB/agar with 100 pg/ml ampicillin and incubated at 37 C overnight). Single colonies of CJ236 cells were then grown in 50 ml 2YT media to midlog phase; 10 pl VCS helper phage (Stratagene) were then added and the mixture incubated at 37 C overnight. Single-stranded
DNA was isolated from the supernatant by precipitation of phage (1/5 volume 20% PEG 8000/2.5
M NaCl; centrifuge at 12K for 15 minutes.). Single-stranded DNA was then isolated from phage using Qiagen single-stranded DNA kit.
Site-directed mutagenesis was accomplished as follows. Oligonucleotides were dissolved to a concentration of 10 OD and phosphorylated on the 5’ end (2 pl oligonucleotide, 2 ul 10 mM ATP, 2 pul 10x Tris-magnesium chloride buffer, 1 ul 100 mM DTT, 10 pul water, 1 ul T4 PNK; incubate at 37 C for 45 minutes). Phosphorylated oligonucleotides were then annealed to single-stranded
DNA template (2 pl single-stranded plasmid, 1 pl oligonucleotide, 1 pl 10x TM buffer, 6 pl water; heat at 94 C for 2 minutes, 50 C for 5 minutes, cool to room temperature). Double-stranded DNA was then prepared from the annealed oligonucleotide/template (add 2 pul 10x TM buffer, 2 ul 2.5 mM dNTPs, 1 pl 100 mM DTT, 1.5 pl 10 mM ATP, 4 pl water, 0.4 ul T7 DNA polymerase, 0.6 jl T4 DNA ligase; incubate at room temperature for two hours). E. coli (XL1 blue, Stratagene) was . then transformed with the double-stranded DNA (1 ul double-stranded DNA, 10 pl 5x KCM, 40 ul water, 50 ul DMSO competent cells; incubate 20 minutes at 4 C, 10 minutes at room temperature), plated onto LB/agar containing 100 pg/ml ampicillin, and incubated at 37 C overnight.
Approximately four colonies from each plate were used to inoculate 5 ml 2YT containing 100 pg/ml ampicillin; these cultures were grown at 37 C for 18-24 hours. Plasmids were then isolated from the cultures using Qiagen miniprep kit. These plasmids were sequenced to determine which
IL1R2D-FB clones contained the desired mutation.
Sequencing of ILIR2D genes was accomplished as follows. The concentration of plasmid DNA was quantitated by absorbance at 280 nm. 800 ng of plasmid was mixed with sequencing reagents (8 pl DNA, 3 ul water, 1 pl sequencing primer, 8 ul sequencing mixture with Big Dye [Applied
Biosystems]). The sequencing primers used were FB Forward and FB Reverse, shown below.
FB Forward TATTCCGGATTATTCATACC SEQ ID NO:74
FB Reverse CCTCTACAAATGTGGTATGGC SEQ ID NO:75
The mixture was then run through 2a PCR cycle (96 C, 10s; 50 C, 55; 60 C 4 minutes; 25 cycles) and the DNA reaction products were precipitated (20 pl mixture, 80 ul 75% isopropanol; incubated 20 minutes at room temperature, pelleted at 14 K rpm for 20 minutes; wash with 250 ul 70% ethanol; heat 1 minute at 94 C). The precipitated products were then suspended in Template
Suppression Buffer (TSB, Applied Biosystems) and the sequence read and analyzed by an Applied
Biosystems 310 capillary gel sequencer. In general, 3 out of 4 of the plasmids contained the desired mutation. A listing of the constructs and their mutant(s) is given below, although any cysteine mutants can be made in any of the given contexts.
Construct Mutant(s) sILIR2D-N83H-FB E11C, 113C, V16C, Q108C, I110C, K112C, K114C, V117C,
V124C, Y127C, E129C sILIR2D-N83H-FBHT E11C, I113C, V16C, Q108C, I110C, K112C, Q113C, K114C,
V117C, V124C, Y127C, E129C sILIR2D-N176H-FB El1C sILIR2D-N176H-FBHT E11C, V16C, V124C, E129C sILIR2D2M-FB E11C, K12C, I13C, A107C,K112C, V124C, Y127.
Mutagenic Oligonucleotides
El1C TAARATTATTTTACATTCACGTTCC SEQ ID NO:76
K12C CACTAAAATTATACATTCTTCACGTTC SEQ ID NO:77 113C TGACACTAAAATACATTTTTCTTCACG SEQ ID NO:78
RX VieC ATTTGCAGATGAACATADAATTATTT SEQ ID NO:79
Al107C AAATATGGCTTGGCAATTATAACATAAG SEQ ID NO:80
Q108C CTTAAATATGGCGCATGCATTATAACA SEQ ID NO:81 1110C GTTTCTGCTTAAAGCAGGCTTGTGCATT SEQ ID NO:82
K112C GGGTAGTTTCTGACAAAATATGGC SEQ ID NO:83
Q113C AACGGGTAGTTTACACTTAAATATGGC SEQ ID NO:84
K114C CTGCAACGGGTAGGCACTGCTTARATATG SEQ ID NO:85
V117C CTCCGTCTCCTGCACAGGGTAGTTTCTG SEQ ID NO:86
V124C CATATAAGGGCAACAAAGTCCTCC SEQ ID NO:87
Y127C AAAAAACTCCATACAAGGGCACACAAG SEQ ID NO:88
E129C TTTAAAAAAACACATATAAGGGCA SEQ ID NO:89
Expression of IL-1 R mutant proteins
All ILIR-FB/FBHT plasmids were site-specifically transposed into the baculovirus shuttle vector (bacmid) by transforming the plasmids into DH10bac (Gibco/BRL) competent cells as follows: 1 ul DNA at 5 ng/pul, 10 pl 5x KCM [0.5 M KCl, 0.15 M CaCl, 0.25 M MgCl,], 30 ul water was mixed with 50 pul PEG-DMSO competent cells, incubated at 4 C for 20 minutes, 25 C for 10 minutes, add 900 pl SOC and incubate at 37 C with shaking for 4 hours, then plated onto LB/agar plates containing 50 pg/ml kanamycin, 7 pg/ml gentamycin, 10 ug/ml tetracycline, 100 pg/ml
Bluo-gal, 10 pg/ml IPTG. After incubation at 37 C for 24 hours, large white colonies were picked and grown in 3 ml 2YT media overnight. Cells were then isolated and double-stranded DNA was extracted from the cells as follows: pellet was resuspended in 250 pl of Solution 1 [15 mM Tris- ' HCI (pH 8.0), 10 mM EDTA, 100 ug/ml RNase A]. 250 ul of Solution 2 [0.2 N NaOH, 1% SDS] was added, mixed gently and incubated at room temperature for 5 minutes. 250 pl 3 M potassium acetate was added and mixed, and the tube placed on ice for 10 minutes. The mixture was centrifuged 10 minutes at 14,000x g and the supernatant transferred to a tube containing 0.8 ml isopropanol. The contents of the tube were mixed and placed on ice for 10 minutes; centrifuged 15 minutes at 14,000x g. The pellet was washed with 70% ethanol and air-dried and the DNA resuspended in 40 ul TE.
The bacmid DNA was used to transfect S{9 cells. Sf9 cells were seeded at 9 x 10° cells per 35 mm well in 2 ml of ${-900 II SFM medium containing 0.5x concentration of antibiotic-anuimycotic and allowed to attach at 27 C for 1 hour. During this time, 5 pl of bacmid DNA was diluted into 100 ul of medium without antibiotics, 6 pl of CelIFECTIN reagent was diluted into 100 pl of medium without antibiotics and then the 2 solutions were mixed gently and allowed to incubate for 30 minutes at room temperature. The cells were washed once with medium without antibiotics, the medium was aspirated and then 0.8 ml of medium was added to the lipid-DNA complex and overlaid onto the cells. The cells were incubated for 5 hours at 27 C, the transfection medium was removed and 2 ml of medium with antibiotics was added. The cells were incubated for 72 hours at 27 C and the virus was harvested from the cell culture medium.
The virus was amplified by adding 0.5 ml of virus to a 50 ml culture of Sf9 cells at 2 x 10° cells/ml and incubating at 27 C for 72 hours. The virus was harvested from the cell culture medium and this stock was used to express the various ILIR constructs in High-Five cells. A 1 L culture of
High-Five cells at 1 x 10° cells/ml was infected with virus at an approximate MOI of 2 and incubated for 72 hours. Cells were pelleted by centrifugation and the supernatant was loaded onto an ILIR antagonist column at I ml/min, washed with PBS followed by a wash with Buffer A (0.2
M NaOAc pH 5.0, 0.2 M NaCl). The protein was eluted from the column by running a gradient from 0-100% of Buffer B (0.2 M NaOAc pH 2.5, 0.2 M NaCl) in 10 minutes followed by 15 minutes of 100% Buffer B at 1 ml/min collecting 2 ml fractions in tubes containing 300 ul of unbuffered Tris. The appropriate fractions were pooled, concentrated and dialyzed against 5 L of 50 mM Tris pH 8.0, 100 mM NaCl at 4 C and filtered through a 0.2 um filter.
EXAMPLE 6
Carpase-3 (aeoiasion smi ns piper ANLCASASE) (CASES) involved in the apoptosis of cells. It exists as the inactive proform, and can be processed by caspases 8, 9, or 10 to form a small subunit and a large subunit, which heterodimerize to constitute the active form. Caspases that are substrates for caspase-3 in the cascade are caspase-6, caspase-7 and caspase-9. Caspase-3 has been shown to be the important for the cleavage of amyloid-beta precursor protein 4A. This ] cleavage has been linked to the deposition of Abeta peptide deposition and death of neurons in
Alzheimers disease and hippocampal neurons following ischemic and exitoxic brain injury. There is a crystal structure available for caspase-3 [1CP3, Mitt], P. R., et al., J Biol Chem 272:6539-6547 (1997).
Cloning of Human Caspase-3
The human version of caspase-3 (also known as Yama, CPP32 beta) was cloned directly from
Jurkat cells (Clone E6-1; ATCC). Briefly, total RNA was purified from Jurkat cells growing at 37 . C/5% CO, using Tri-Reagent (Sigma). Oligonucleotide primers were designed to allow DNA encoding the large and small subunits of Caspase-3/Yama/CPP32 to be amplified by polymerase . chain reaction (PCR). Briefly, DNA encoding amino acids 28-175 (encompassing most of the large subunit) was directly amplified from 1 pg total RNA using Ready-To-Go-PCR Beads (Amersham/Pharmacia) and the following oligonucleotides: casp-3 large for TTCCATATGTCTGGAATATCCCTGGACAACAGTTA SEQ ID NO:90 casp-3 large rev AAGGAATTCTTAGTCTGTCTCAATGCCACAGTCCAG SEQ ID NO:91
DNA encoding amino acids 176-277 (encompassing most of the small subunit) was directly amplified from 1 pug total RNA using Ready-To-Go-PCR Beads (Amersham/Pharmacia) and the following oligonucleotides: casp-3 small for TTCCATATGAGTGGTGTTGATGATGACATGGCG SEQ ID NO:92 casp-3 small rev AAGGAATTCTTAGTGATARARATAGAGTTCTTTTGTGAG SEQ ID NO:93
Amplified DNA corresponding to either the large subunit or the small subunit of caspase-3 was then cleaved with the restriction enzymes EcoRI and Ndel and directly cloned using standard molecular biology techniques into pRSET-b (Invitrogen) digested with EcoRI and Ndel. [See e.g.,
Tewari. M., et al., Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase, Cell 81: 801-809 (1995)].
Generation of Casp-3 Cys Mutations
Plasmids containing DNA encoding either the large or small subunits of Caspase-3 were separately transformed into E. coli K12 CJ236 cells (New England BioLabs) and cells containing each construct were selected by their ability to grow on ampicillin containing agar plates. Overnight cultures of the large and small subunits were individually grown in 2YT (containing 100 pg/mL of ampicillin) at 37 C. Each culture was diluted 1:100 and grown to Ago = 0.3-06. A 1.5 mL sample of each culture was removed and infected with 10 uL of phage VCS-M13 (Stratagene), shaken at 37 C for 60 minutes, and an overnight culture of each was prepared with 1 mL of the infected culture diluted 1:100 in 2YT with 100 pg/mL of ampicillin and 20 pg/ml of chloramphenicol and grown at 37 C. Cells were centrifuged at 3000 rcf for 10 minutes and 1/5 volume of 20%PEG/2.5 M NaCl was added to the supernatant. Samples were incubated at room temperature for 10 minutes and then centrifuged at 4000 rcf for 15 minutes. The phage pellet was resuspended in PBS and spun at 15 K rpm for 10 minutes to remove remaining particulate matter.
Supernatant was retained, and single stranded DNA was purified from the supernatant following procedures for the QIA prep spin M13 kit (Qiagen).
Mutagenic Oligonucleotides
Cysteine mutations in the small subunit were made with the corresponding primers:
Y204C TCGCCAAGAACAATAACCAGG SEQ ID NO:94
S209C GCCATCCTTACAATTTCGCCA SEQ ID NO:95 wW214C CTGGATGAAACAGGAGCCATC SEQ ID NO:96
S251C AGCGTCAAAGCAAAAGGACTC SEQ ID NO:97
F256C CTTTGCATGACAAGTAGCGTC SEQ ID NO:98
Cysteine mutations in the large subunit were made with the corresponding primers:
M61C CCGAGATGTACATCCAGTGCT SEQ ID NO:99
T62C AGACCGAGAACACATTCCAGT SEQ ID
NO:100
S65C ATCTGTACCACACCGAGATGT SEQ ID
NO:101
Hi121C TTCTTCACCACAGCTCAGAAG SEQID
NO:102
L168C GCCACAGTCACATTCTGTACC SEQID
NO:103
Approximately 100 pmol of each primer was phosphorylated by incubating at 37 C for 60 minutes in buffer containing 1X TM Buffer (0.5 M Tris pH 7.5, 0.1 M MgCl, ), | mM ATP, S mM DTT, and 5U T4 Kinase (NEB). Kinased primers were annealed to the template DNA in a 20 pL reaction volume (~50 ng kinased primer, 1X TM Buffer, and 10-50 ng single-stranded DNA) by incubation at 85 C for 2 minutes, 50 C for 5 minutes, and then at 4 C for 30-60 minutes. An extension cocktail 2 mM ATP, 5 mM dNTPs, 30 mM DTT, T4 DNA ligase (NEB), and T7 polymerase (NEB)) was added to each annealing reaction and incubated at room temperature for 3 hours.
Mutagenized DNA was transformed into E. coli XL1-Blue cells, and colonies containing plasmid
DNA selected were for by growth on LB agar plates containing 100 pg/ml ampicillin. DNA sequencing was used to identify plasmids containing the appropriate mutation.
Expression of Casp-3 Mutant Proteins . Plasmid DNA encoding cysteine mutations in the large subunit were transformed into Codon Plus
BL21 Cells and plasmid DNA encoding cysteine mutations in the small subunit were transformed into BL21 (DE3) pLysS Cells. Codon Plus BL21 Cells containing plasmids encoding wild-type and cysteine mutated versions of the large subunit were grown in 2YT containing 150 pg/mL of ampicillin overnight at 37 C and immediately harvested. BL21 pLysS cells containing plasmids encoding wild-type and cysteine mutated versions of the small subunit were grown in 2YT at 37 C with 150 pg/mL of ampicillin until Ago = 0.6. Cultures were subsequently induced with 1mM
IPTG and grown for an additional 3-4 hours at 37 C. After harvesting cells by centrifuging at 4K rpm for 10 minutes, the cell pellet was resuspended in Tris-HCI (pH 8.0)/S mM EDTA and micro fluidized twice. Inclusion bodies were isolated by centrifugation at 9K rpm for 10 minutes and then resuspended in 6 M guanidine hydrochloride. Denatured subunits were rapidly and evenly diluted to 100 pg/mL in renaturation buffer (100 mM Tris/KOH (pH 8.0), 10% sucrose, 0.1% CHAPS, 0.15 M NaCl, and 10 mM DTT) and allowed to renature by incubation at room temperature for 60 minutes with slow stirring.
Renatured proteins were dialyzed overnight in buffer containing 10 mM Tris (pH 8.5), 10 mM
DTT, and 0.1 mM EDTA. Precipitate was removed by centrifuging at 9K rpm for 15 minutes and filtering the supernatant through a 0.22 um cellulose nitrate filter. The supernatant was then loaded onto an anion-exchange column (Uno5 Q-Column (BioRad)), and correctly folded caspase-3 protein was eluted with a 0-0.25 M NaCl gradient at 3 mL/min. Aliquots of each fraction were electrophoresed on a denaturing polyacrylamide gel and fractions containing Caspase-3 protein were pooled.
EXAMPLE 7 (PTP-1B) . PTP-1B (accession number SWS P18031) is a tyrosine phosphatase that has a C-terminal domain that is associated to the endoplasmic reticulum (ER) and a phosphatase domain that faces the - cytoplasm. The proteins that it dephosphorylates are transported to this location by vesicles. The activity of PTP-1B is regulated by phosphorylation on serine and protein degradation. PTP-1Bis a negative regulator of insulin signaling, and plays a role in the cellular response to interferon stimulation. This phosphatase may play a role in obesity by decreasing the sensitivity of organisms to leptin, thereby increasing appetite. Additionally, PTP-1B plays a role in the control of cell growth. A crystal structure has been solved for PTP-1B [1PTY, Puius, Y. A., et al., Proc Natl Acad
Sci US A 94: 13420-13425 (1997)].
Cloning of human PTP-1B
Full length human PTP-1B is 435 amino acids in length; the protease domain comprises the first 288 amino acids. Because truncated portions of PTP-1B comprising the protease domain is fully : active, various truncated versions of PTP-1B are often used. A cDNA encoding the first 321 amino acids of human PTP-1B was isolated from human fetal heart total RNA (Clontech).
Oligonucleotide primers corresponding to nucleotides 91 to 114 (For) and complementary to nucleotides 1030 to 1053 (Rev) of the PTP-1B cDNA [Genbank M31724.1, Chernoff, J., et al.,
Proc. Natl. Acad. Sci. U. S. A. 87: 2735-2739 (1990)] were synthesized and used to generate a DNA using the polymerase chain reaction.
Forward GCCCATATGGAGATGGAAAAGGAGTTCGAG SEQ ID
NO:104
Rev GCGACGCGAATTCTTAATTGTGTGGCTCCAGGATTCGTTT SEQ ID
NO:105
The primer Forward incorporates an Ndel restriction site at the first ATG codon and the primer Rev inserts a UAA stop codon followed by an EcoR1 restriction site after nucleotide 1053. cDNAs were digested with restriction nucleases Ndel and EcoRI and cloned into pRSETc (Invitrogen) using standard molecular biology techniques. The identity of the isolated cDNA was verified by DNA sequence analysis (methodology is outlined in a later paragraph).
A shorter cDNA, PTP-1B 298, encoding amino acid residues 1-298 was generated using oligonuclotide primers Forward and Rev2 and the clone described above as a template in a polymerase chain reaction.
Rev? TGCCGGAATTCCTTAGTCCTCGTGGGAAAGCTCC SEQ ID
NO:106
Generation of PTP-1B Cysteine Mutants
Site-directed mutants of PTP-1B (amino acids 1-321), PTP-1B 298 (amino acids 1-298) and PTP- 1B 298-2M (with Cys32 and Cys92 changed to Ser and Val, respectively) were prepared by the single-stranded DNA method (modification of Kunkel, 1985). 298-2M was made with the following oligonucleotides.
C328 CTTGGCCACTCTAGATGGGAAGTCACT SEQ ID
NOC:107 cov CCRAAAGTGACCGACTGTGTTAGGCAA SEQID
NO:108
Oligonucleotides were designed to contain the desired mutations and 12 bases of flanking sequence on each side of the mutation. The single-stranded form of the PTP-1B/pRSET, PTP-1B 298/pRSET and PTP-1B 298-2M/pRSET plasmid was prepared by transformation of double-stranded plasmid into the CJ236 cell line (1 pl double-stranded plasmid DNA, 2 pl 5x KCM salts, 7 ul water, 10 pl
PEG-DMSO competent CJ236 cells; incubated on ice for 20 minutes followed by 25 C for 10 minutes; plated on LB/agar with 100 pg/ml ampicillin and incubated at 37 C overnight). Single colonies of CJ236 cells were then grown in 100 ml 2YT media to midlog phase; 5 ul VCS helper phage (Stratagene) were then added and the mixture incubated at 37 C overnight. Single-stranded
DNA was isolated from the supernatant by precipitation of phage (1/5 volume 20% PEG 8000/2.5M NaCl; centrifuge at 12K for 15 minutes). Single-stranded DNA was then isolated from phage using Qiagen single-stranded DNA kit.
Site-directed mutagenesis was accomplished as follows. Oligonucleotides were dissolved in TE (10 mM Tris pH 8.0, ImM EDTA) to a concentration of 10 OD and phosphorylated on the 5’ end (2 pl oligonucleotide, 2 pl 10 mM ATP, 2 pl 10x Tris-magnesium chloride buffer, 1 pul 100 mM DTT, 12.5 ul water, 0.5 ul T4 PNK; incubate at 37 C for 30 minutes). Phosphorylated oligonucleotides were then annealed to single-stranded DNA template (2 pl single-stranded plasmid, 0.6 ul oligonucleotide, 6.4 pl water; heat at 94 C for 2 minutes, slow cool to room temperature). Double- stranded DNA was then prepared from the annealed oligonucleotide/template (add 2 ul 10x TM buffer, 2 pl 2.5 mM dNTPs, 1 pl 100 mM DTT, 0.5 pl 10 mM ATP, 4.6 ul water, 0.4 nl T7 DNA polymerase, 0.2 pl T4 DNA ligase; incubate at room temperature for two hours). E. coli (XL1 blue,
Stratagene) were then transformed with the double-stranded DNA (5 pl double-stranded DNA, 5 ul 5x KCM, 15 pl water, 25 ul PEG-DMSO competent cells; incubate 20 minutes on ice, 10 min. at room temperature), plated onto LB/agar containing 100 pg/ml ampicillin, and incubated at 37 C . overnight. Approximately four colonies from each plate were used to inoculate § ml 2YT containing 100 pg/ml ampicillin; these cultures were grown at 37 C for 18-24 hours. Plasmids . were then isolated from the cultures using Qiagen miniprep kit. These plasmids were sequenced to determine which clones contained the desired mutation.
A listing of the constructs and the single mutations to cysteine made in each context is given below.
Construct Mutants
PTP-1B 321 H25C, D29C, R47C, D48C, S50C, K120C, M258C
PTP-1B 298 H25C, D29C, D48C, S50C, K120C, M258C, F280C :
PTP-1B 298-2M E4C, E8C, H25C, A27C, D29C, K36C, Y46C, R47C, D48C,
V49C, S50C, F52C, K120C, S151C, Y152C, T178C, D18IC,
F182C, E186C, S187C, A189C, K197C, E200C, L272C, E276C, 1218C, M258C, Q262C, V287C
However, it should be understood that any of the site-directed mutants may be made in any construct of PTP-1B. For example, another construct is another truncated version of PTP-1B having residues 1-382, shown as SEQ ID NO:109 below. 1 MEMEKEFEQI DKSGSWAAIY QDIRHEASDF PCRVAKLPKN KNRNRYRDVS PFDHSRIKLH 61 QEDNDYINAS LIKMEEAQRS YILTQGPLPN TCGHFWEMVW EQKSRGVVML NRVMEKGSLK 121 CAQYWPQKEE KEMIFEDTNL KLTLISEDIK SYYTVRQLEL ENLTTQETRE ILHFHYTTWP 181 DFGVPESPAS FLNFLFKVRE SGSLSPEHGP VVVHCSAGIG RSGTFCLADT CLLLMDKRKD 241 PSSVDIKKVL LEMRKFRMGL IQTADQLRFS YLAVIEGAKF IMGDSSVQDQ WKELSHEDLE 301 PPPEHIPPPP RPPKRILEPH NGKCREFFPN HQWVKEETQE DKDCPIKEEK GSPLNAAPYG 361 IESMSQDTEV RSRVVGGSLR GA
Mutagenic Oligonucleotides
EAC CTCGAACTCCTTGCACATCTCCATATG SEQID
NO:110
ESC CTTGTCGATCTGGCAGAACTCCTTTTC SEQ ID
NO:111
H25C GTCACTGGCTTCACATCGGATATCCTG SEQ ID
NO:112
A27C TGGGAAGTCACTGCATTCATGTCGGAT SEQ ID
NO:113
D29C TCTACATGGGAAGCAACTGGCTTCATG SEQ ID
NO:114
K36C GTTCTTAGGAAGACAGGCCACTCTACA SEQ ID
NO:115 :
Y46C ACTGACGTCTCTGCACCTATTTCGGTT SEQ ID
NO:116 :
R47C GGGACTGACGTCACAGTACCTATTTCG SEQID
NO:117
D48C AAAGGGACTGACGCATCTGTACCTATT SEQ ID
NO:118
V49C GTCAAAGGGACTGCAGTCTCTGTACCT SEQ ID
N NO:119
S50C CTATGGTCARAGGGACAGACGTCTCTGTACC SEQ ID “ NO:120
F52C CCGACTATGGTCACAGGGACTGACGTC SEQ ID
NO:121
K120C GTATTGTGCGCAACATAACGAACCTTT SEQ ID
NO:122
S151C CACTGTATAATAGCACTTGATATCTTC SEQ ID
NO:123
Y152C GTCGCACTGTATAACATGACTTGATATC SEQ ID
NO:124
T178C CAAAGTCAGGCCAGCAGGTATAGTGGAA SEQ ID
NO: 125
DISIC AGGGACTCCAARAGCAAGGCCATGTGGT SEQ ID
NO:126
E186C GAATGAGGCTGGTGAGCAAGGGACTCCAAAG SEQ ID
NO:127
S187C GAATGAGGCTGGGCATTCAGGGACTCC SEQ ID
NO:128
A189C GTTCAAGAATGAGCATGGTGATTCAGG SEQ ID
NO:129
K197C CTGACTCTCGGACGCAGAAAAGAAAGTTC SEQ ID
NO:130
E200C GAGTGACCCTGAGCATCGGACTTTGAAAAG SEQ ID
NO:131
M258C CTGGATCAGCCCACACCGAAACTTCCT SEQ 1D
NO:132
Q262C CTGGTCGGCTGTACAGATCAGCCCCAT SEQ ID
NO:133 1L.272C CTTCGATCACAGCGCAGTAGGAGAAGCG SEQ iD
NO:134
E276C GAATTTGGCACCGCAGATCACAGCCAG SEQ ID
NO:135
1281C AGAGTCCCCCATGCAGAATTTGGCACC SEQ ID
NO:136
V287C CCACTGATCCTGGCAGGAAGAGTCCCC SEQ ID
NO:137
Besides mutations to cysteines, mutations removing naturally occurring cysteines can also be made.
For example, two different “scrubs” of Cys 215 were made in the PTP-1B 298-2M context using the following oligonucleotides: h)
C215A GATGCCTGCACTGGCGTGCACCACAAC SEQ ID
NO:138
C2158 GATGCCTGCACTGGAGTGCACCACAAC SEQ ID
NO:139
In the PTP-1B 298 context, two quadruple mutants were made using the C92A oligonucleotide shown below. They are C328, C92A, V287C, C215A, which used SEQ ID NO:107 SEQ ID
NO:140 SEQ ID NO:137 and SEQ ID NO:138 and C328, C92A, E276C, C215A, which used SEQ
ID NO:107, SEQ ID NO:140 SEQ ID NO:135 and SEQ ID NO:138.
C92A CCARAAGTGACCGGCTGTGTTAGGCAA SEQ ID
NO:140
Sequencing of PTP-1B clones was accomplished as follows. The concentration of plasmid DNA was quantitated by absorbance at 280 nm. 1000 ng of plasmid was mixed with sequencing reagents (1 pg DNA, 6 ul water, 1 pl sequencing primer at 3.2 pm/pl, 8 pl sequencing mixture with Big Dye [Applied Biosystems]). The sequencing primers are SEQ ID NO:17 and SEQ ID NO:18. The mixture was then run through a PCR cycle (96 C,105;50 C, 5s; 60 C 4 minutes; 25 cycles) and the DNA reaction products were precipitated (20 ul mixture, 80 ul 75% isopropanol; incubated 20 minutes at room temperature then pelleted at 14 K rpm for 20 minutes; wash with 250 pl 75% isopropanol; heat 1 minute at 94 C). The precipitated products were then resuspended in 20 ul
TSB (Applied Biosystems) and the sequence read and analyzed by an Applied Biosystems 310 capillary gel sequencer. In general, 1/4 of the plasmids contained the desired mutation.
Expression of Cysteine Mutants of PTP-1B
Mutant proteins were expressed as follows. PTP-1B clones were transformed into BL21 codon plus cells (Stratagene) (1 pl double-stranded DNA, 2 pl 5x KCM, 7 pl water, 10 pl DMSO competent cells; incubate 20 minutes at 4 C, 10 minutes at room temperature), plated onto LB/agar containing 100 pg/ml ampicillin, and incubated at 37 C overnight. 2 singie colonies were picked off the plates or from frozen glycerol stocks of these mutants and inoculated in 100 ml 2YT with 50 pg/ml carbenicillin and grown overnight at 37 C. 50 ml from the overnight cultures were added to 1.5 L of 2YT/carbenicillin (50 pg/ml) and incubated at 37 C for 3-4 hours until late-log phase v (absorbance at 600 nm ~0.8-0.9). At this point, protein expression was induced with the addition of
IPTG to a final concentration of 1 mM. Cultures were incubated at 37 C for another 4 hours and - then cells were harvested by centrifugation (7K rpm, 7 minutes) and frozen at 20 C.
PTP-1B proteins were purified from the frozen cell pellets as described in the following. First, cells were lysed in a microfluidizer in 100 ml of buffer containing 20 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT, and 10% glycerol buffer (with 3 passes through a Microfluidizer [Microfluidics 110S]) and inclusion bodies were removed by centrifugation (10K rpm, 10 minutes). Purification of all
PTP-1B mutants was performed at 4 C. The supernatants from the centrifugation were filtered through 0.45 pm cellulose acetate (5 pl of this material was analyzed by SDS-PAGE) and loaded onto an SP Sepharose fast flow column (2.5 cm diameter x 14 cm long) equilibrated in Buffer A (20 mMMES pH 6.5, 1 mM EDTA, 1 mM DTT, 1% glycerol) at 4 ml/min.
The protein was then eluted using a gradient of 0 — 50% Buffer B over 60 minutes (Buffer B: 20 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT, 1% glycerol, | M NaCl). Yield and purity was examined by SDS-PAGE and, if necessary, PTP-1B was further purified by hydrophobic interaction chromatography (HIC). Protein was supplemented with ammonium sulfate until a final concentration of 1.4 M was reached. The protein solution was filtered and loaded onto an HIC column at 4 ml/min in Buffer A2: 25 mM Tris pH 7.5, 1 mM EDTA, 1.4 M (NH,),SO,, 1 mM
DTT. Protein was eluted with a gradient of 0 - 100% Buffer B over 30 minutes (Buffer B2: 25 mM
Tris pH 7.5, 1 mM EDTA, 1 mM DTT, 1% glycerol). Finally, the purified protein was dialyzed at 4 C into the appropriate assay buffer (25 mM Tris pH 8, 100 mM NaCl, 5 mM EDTA, 1 mM DTT, 1% glycerol). Yields varied from mutant to mutant but typically were within the range of 3-20 mg/L culture.
EXAMPLE 8
HIV IN)
HIV IN is one of three key enzyme targets of the human immunodeficiency virus; it removes two nucleotides from each 3° end of the originally blunt viral DNA, and inserts the viral DNA into the host DNA by strand transfer. The integration process is completed by host DNA repair enzymes.
HIV IN has three distinct domains: the N-terminal domain, the catalytic core domain, and the C- terminal domain. Although the X-ray crystal structures of each of these isolated domains have been solved, it is not yet clear how they interact with each other. Integration is absolutely essential for the replication of the virus and progression of disease, and thus integrase inhibitors can be used in the treatment of HIV/AIDS. Structures of core domain of integrase are available [1EXQ, Chen, J.
C.-H. etal, Proc. Natl. Acad. Sci. U. S. A. 97: 8233-8238 (2000); 1BL3, Maignan, S., et al., J Mol
Biol 282:359-368 (1998); in complex with tetraphenyl arsonium, 1HYZ and 1HYYV. Molten, V_, et , al, Acta Crystallogr D Bio Crystallog., 57:536-544 (2001)].
Cloning of HIV IN
Numbering of the wild type and mutant HIV-1 integrase residues follows the convention of the first amino acid residue of the mature protein being residue number 1, and the HIV-1 integrase catalytic core domain being comprised of residues 52-210 [Leavitt, A. D., et al., J Biol Chem 268: 2113- 2119 (1993)].
A plasmid construct, pT7-7 HT-IN,.r,, encoding the HIV integrase core domain (residues 50-212), having an N-terminal 6x histidine tag and thrombin cleavable linker, and CS6S, W131D, F139D, and F185K mutations in the pT7-7 (Novagen) vector background [Chen, J. C. -H,, et al., Proc. Natl.
Acad. Sci. U. S. A. 97: 8233-8238 (2000)] was obtained from Dr. Andy Leavitt at UCSF. Upon comparison of the crystal structure of this core domain variant [Chen, J. C. -H,, et al., Proc. Natl.
Acad. Sci. U. S. 4. 97: 8233-8238 (2000)] to other integrase core structures, it was noted that the
F139D mutation, designed to increase solubility of the protein, caused a rotation of the side chain that transmitted a distortion to the catalytically important Asp116. The mutation was therefore reverted to the wild-type phenylalanine residue by Quickchange mutagenesis (Stratagene), following manufacturer’s instructions and using SEQ ID NO:141 and SEQ ID NO:142.
D139F1-int GTATCAAACAGGAATTCGGTATCCCGTACAAC SEQ ID NO:141
D139F2-int GTTGTACGGGATACCGAATTCCTGTTTGATACC SEQ ID NO:142
This generated pT7-7 HT-IN,, encoding the triple mutant (C56S, W131D, F185K) of the integrase core, SEQ ID NO: 143. 52 GQVDSSPGIW QLDCTHLEGK VILVAVHVAS GYIEAEVIPA ETGQETAYFL LKLAGRWPVK . 112 TIHTDNGSNF TGATVRAACD WAGIKQEFGI PYNPQSQGVV ESMNKELKKI IGQVRDQAEN 172 LKTAVOMAVF IHNKKRKGGI GGYSAGERIV DI IATDIQT
In preparation for making cysteine mutations at tethering sites, the two wild-type cysteines, (C130 and C65) were replaced by alanine residues and the DNA encoding the His-tagged IN; core domain transferred: into the pRSET A vector, containing an F1 origin of replication that allows preparation of single-stranded plasmid DNA, and thus mutagenesis by the Kunkel method [Kunkel,
T. A, et al.,, Methods Enzymol. 204: 125-139 (1991)]. Replacement of C130 by alanine was accomplished by cassette mutagenesis, using the double stranded cassette composed of SEQ ID
NO:144 and SEQ ID NO:145. The cassette, containing the appropriate overhangs at each end, was ligated into pT7-7 HT-IN,; digested with BsiW1 and EcoRI. * ) C130A cassette | GTACGTGCTGCAGCCGACTGGGCTGGTATCAAACAGG SEQ ID NO: 144
C130A cassette 2 GAATTCCTGTTTGATACCAGCCCAGTCGGCTGCAGCAC SEQ ID NO: 145
The C65A mutation was carried out independently by Quickchange mutagenesis on pT7-7 HT-INy; using SEQ ID NO:146 and SEQ ID NO:147.
C65A1-int ATCTGGCAACTGGACGCGACTCACCTCGAGGGT SEQ ID NO:146
C65A2-int ACCCTCGAGGTGAGTCGCGTCCAGTTGCCAGAT SEQ ID NO: 147 . The DNA encoding HT-C130A integrase core domain was subcloned into the pRSET A vector by
PCR cloning. SEQ ID NO:148 and SEQ ID NO:149 were used as PCR primers, and the resulting amplified product was digested with Ndel and Hind III, and ligated into pRSET A that had been digested with the same enzymes, to generate pRSET-HT-C130A-IN,;.
C130 _rsetF GGAGATATACATATGCACCACCATCACC SEQ ID NO:148
C130 _rsetR ATCATCGATGATAAGCTTCCTAGGTCTGG SEQ ID NO: 149
A BamHI fragment of pT7-7 HT-C65A-IN,; containing the C65A mutation was ligated into pRSET-HT-C130A-IN;, to generate pRSET-HT-INyenpiae. This plasmid served as a template for further Kunkel mutagenesis to introduce cysteine substitutions at positions chosen for tethering.
SEQ ID NO:17 was used for sequencing.
Mutagenic Oligonucleotides ‘ Q62C GTGAGTCGCGTCCAGGCACCAGATACCCGG SEQ iD
NO:150 . D64C CTCGAGGTGAGTCGCGCACAGTTGCCAGATAC SEQ ID
NO:151
T66C CTTTACCCTCGAGGTGACACGCGTCCAGTTGCC SEQ ID
NO:152
H67C GGATAACTTTACCCTCGAGGCAAGTCGCGTCCAGTTG SEQ ID
NO:153
L68C AACTTTACCCTCGCAGTGAGTCGCGTCCA SEQ ID
NO:154
K71C GCAACCAGGATAACGCAACCCTCGAGGTG SEQ ID
NO:155
ESC CAGTTTCCTGACCASTGCAGGCCOGGATARCTTC SEQ ID
NO:156
H114C GGATCCGTTGTCAGTGCAGATGGTTTTAACCGGC SEQ ID
NO:157
D116C GTTGGATCCGTTGCAAGTGTGGATGGTTTTAACCG SEQ ID
NO:158
N120C CGGTAGCACCAGTGAAGCAGGATCCGTTGTCAGTG SEQ ID
NO:159
N144C CACCCTGAGACTGCGGGCAGTACGGGATACCGA SEQ ID
NO:160
Q148C ~~ CATAGATTCAACAACACCGCAAGACTGCGGGTTGT SEQ ID
NO:161 [151C GCTCTTTGTTCATAGATTCGCAAACACCCTGAGA SEQ ID
NO:162
E152C GCTCTTTGTTCATAGAGCAAACAACACCCTGAGA SEQ ID
NO:163
N155C CCGATGATTTTTTTGAGCTCTTTGCACATAGATTCAACAAC SEQ ID
NO:164
K156C CCGATGATTTTTTTGAGCTCGCAGTTCATAGATTC SEQID
NO:165
K159C CCTGACCGATGATTTTGCAGAGCTCTTTGTTCAT SEQ ID
NO:166
G163C CCTGATCACGAACCTGGCAGATGATTTTTTTG SEQ ID
NO:167
Q168C GGTTTTCAGGTGTTCAGCGCAATCACGAACCTGA SEQID
NO:168
T174C GCCATCTGAACCGCGCATTTCAGGTGTTCAGCC SEQID
NO:169
Expression of IN Cysteine Mutants pT7-7 and pRSET integrase core domain expression plasmids were transformed into BL21star E. coli (Invitrogen) by standard methods, and a single colony from the resulting plate was used to inoculate 250 mL of 2x YT broth containing 100 pg/mL ampicillin. Following overnight growth at 37 C, the cells were harvested by centrifugation at 4K rpm and resuspended in 100 mL 2YT/amp. 40 mL of the washed cells was used to inoculate 1.5 L of the same media, and after growth at 37 C to an OD at 600 nm of between 0.5 and 0.8, the culture was moved to 22 C and allowed to cool.
IPTG was added to a final concentration of 0.1 mM and expression continued 17-19 h at 22 C.
Cells were harvested by centrifugation at 4K rpm. Cell pellets were resuspended in 100 mL Wash 5 buffer (Wash 5: 20 mM Tris-HCl, 1 M MgClz, 5 mM imidazole, S mM B-mercaptoethanol, pH 7.4)
and lysis was accomplished by sonication for 1 minute, repeated a total of 3 times with 2 minutes rest between. Cell debris was removed by centrifugation at 14K rpm followed by filtration.
Integrase core domain was purified by affinity chromatography on Ni-NTA superflow resin . (Qiagen) at 4 C. After loading the cell lysate, the column was washed with Wash 40 buffer (Wash 40: 20 mM Tris-HCl, 0.5 M NaCl, 40 mM imidazole, 5 mM B-mercaptoethanol, pH 7.4) and His- . tagged IN core domain eluted with E400 buffer (E400: 20 mM Tris-HCI, 0.5 M NaCl. 400 mM imidazole, 5 mM B-mercaptoethanol). The purified enzyme was dialyzed versus 20 mM Tris, 0.5
M NaCl, 2.5 mM CaClz, 5 mM B-mercaptoethanol, pH 7.4 at 4 C, and aliquoted into 1.5 mL tubes.
Biotinylated thrombin (Novagen) (2U thrombin/mg of protein) was added and the tubes rotated overnight at 4 C, followed by thrombin removal using streptavidin-agarose resin (Novagen) and separation of His-tagged protein and peptides from the cleaved material by passage through a second column of Ni-NTA sepharose fast-flow. Purified, cleaved integrase core domain was dialyzed against 20 mM Tris-HCl, 0.5 M NaCl, 3 mM DTT, and 5% glycerol, pH 7.4, and stored at -20 C. Protein concentrations were determined by absorbance at 280 nm after desalting on NAP-5 columns (Pharmacia), using E250" = (1.174), and molecular weights confirmed by ESI mass spectrometry (Finnigan).
EXAMPLE 9 BACE]I (accession number SWS 56817) is a type! integral glycoprotein that is an aspartic protease.
Found mostly in the Golgi, BACEI cleaves the amyloid precursor protein to form the Abeta peptide. A strong association has been shown between deposition of this peptide on the cerebrum and Alzheimer’s disease; therefore BACEI is one of the primary targets for this disease. A crystal structure of BACEI has been solved {IFKN, Hong, L. et al., Science 290:150-153 (2000)).
Cloning of Humar BACE1
The proprotease domain gene sequence (bases 64-1362, amino acid residues 22-454) was subcloned from pFBHT into the E. coli expression vector pRSETC by PCR, to create pB22, which served as a template for mutagenesis to incorporate cysteine tethering sites. For a description of pFBHT, a modified pFastBac plasmid, see example 4 above. The subcloning was accomplished as follows. . The cDNA encoding full-length human BACE], bases 1-1551, starting from the initiator Met codon and including an extra 48 bases of mRNA transcript following the stop codon [Vassar, R., et al., : Science 286: 735-741 (1999)] was obtained by a combination of PCR cloning of the 3’ 1425 bases from human cDNA libraries, and synthesis of the remaining 5’ 126 bases by serial overlapping
PCR. All PCR reactions were performed using Advantage2 polymerase (Clontech) according to manufacturers instructions. A fragment spanning bases 126-374 was obtained by PCR from a human cerebral cortex library and SEQ ID NO:170 and SEQ ID NO:171; a fragment spanning bases 339-770 was obtained by PCR from a Stratagene Unizap XR human brain cDNA library, and
SEQ ID NO:172 and SEQ ID NO:173; and the 3” end fragment, spanning bases 735-1551, was obtained by PCR from a human brain library, using SEQ ID NO:174 and SEQ ID NO:175. The three fragments, having 35 bp of overlap at the junctions, were gel purified and combined in one
PCR reaction, using primers to the ends (SEQ ID NO:170 and SEQ ID NO:176) to amplify the 126- : 1551 product.
For2 GCTGCCCCGGGAGACCGACGAAGA SEQ ID NO:170 midRev?2 CGGAGGTCCCGGTATGTGCTGGAC SEQ ID NO:171 midFor CCAGAGGCAGCTGTCCAGCACATA SEQ ID NO:172 midRev] TCCCGCCGGATGGGTGTATACCAG SEQ ID NO:173
BACEl4 GTACACAGGCAGTCTCTGGTATACACC SEQ ID NO:174
BACE1l1l GTGTGGTCCAGGGGAATCTCTATCTTCTG SEQ IDNO:175
BACES GTCATCGTCTCGAGTCACTTCAGCAGGGAGATGTCATCAG SEQ ID NO:176
The 126-1551 piece, and the subsequent elongated products, were used as a templates for serial overlapping PCR reactions, to add the remaining 5° —126 bases using SEQ ID NO:177, SEQ ID
NO:178 and SEQ ID NO:179 as forward primers, with SEQ ID NO:176 always at the reverse primer.
BACEfill2
CGGCTGCCCCTGCGCAGCGGCCTGEGEGGCECCCCCCTGGGGCTGCGGCTGCCCCGGGAG
SEQ ID NO:177
BACE filll
ATGGGCGCGGGAGTGCTGCCTGCCCACGGCACCCAGCACGGCATCCGGCTGCCCCTECGC
SEQ ID NO:178
BACE for-EcoRI :
CCGGAATTCATGGCCCAAGCCCTGCCCTGGCTCCTGCTCTGGATGGGCGCGGGAGTS
SEQ ID NO:179 ‘
SEQID NO:179 and SEQ ID NO:176 contained EcoRI and Xhol restriction sites, respectively, and digestion of the PCR product, along with the Baculovirus expression vector, pFBHT, with the same enzymes was followed by gel purification and ligation of the resulting DNA fragments, yielding the construct, pFBHT-BACE. This construct was used as a template for PCR amplification of bases 1- 1362, corresponding to the preproBACE soluble protease domain, using SEQ ID NO:180 and SEQ
ID NO:181. . proFor-Nde CGCCATATGGCGGGAGTGCTGCCTGCCCACGGC SEQ ID NO:180
BACErev-RI CCGGAATTCTCAGGTTGACTCATCTGTCTGTGGAAT SEQ ID NO:181
SEQ ID NO:180 and SEQ ID NO:181 contained Ndel and EcoRI restriction sites, respectively, and digestion of the PCR product, along with the E. coli expression vector, pRSETC, with the same enzymes was followed by gel purification and ligation of the resulting DNA fragments led to the construct pB1. Vector pB1 was then used as a template for Kunkel mutagenesis (Kunkel, T. A., et al., Methods Enzymol. 154:367-382 [1987]) to delete the BACE presequence (bases 1-63), producing the construct pB22. pB22 served as a template for mutagenesis to incorporate cysteine tethering sites, using either the Kunkel method or a Quickchange mutagenesis kit (Stratagene). Mutagenenic Oligonucleotides
L91C GCCTGTATCCACGCAGATGTTGAGCGT SEQ ID
NO:182
T133C CTTGCCCTGGCAGTAGGGCACATACCA SEQ ID
NO:183
Q134C TTCCCACTTGCCGCAGGTGTAGGGCAC SEQ ID
NO:184
F169C CGTTGATGARGCACTTGTCTGATTCGC SEQ ID
NO:185 1171C GTTGGAGCCGTTGCAGAAGAACTTGTC SEQ ID
NO:186
R189C GGAGTCGTCAGGACAGGCAATCTCAGC SEQ ID
NO:187
Y259C GATGACCTCATAACACCACTCCCGCCG SEQ ID
NO:188
N294C GGGCAAACGAAGGCAGGTGGTGCCACT SEQ ID
NO:189
R296C TTTCTTGGGCAAACAAAGGTTGGTGGT SEQ ID
NO:190
T390C CATAACAGTGCCGCAGGATGACTGTGA SEQ ID . NO:191
V393C AACAGCTCCCATACAAGTGCCCGTGGA SEQ ID
NO:192
Expression of Human BACE1 Mutants pB22 was transformed into BL21star E. coli (Invitrogen) by standard methods, and a single colony from the resulting plate was used to inoculate 50 mL of 2xYT broth containing 100 pg/mL ampicillin. Following overnight growth at 37 C, 40 mL of the culture was used to inoculate 1.5 L
S of the same media. and after growth at 37 C to an OD at 600 nm of between 0.5 and 0.8, IPTG was added to a final concentration of 1.0 mM and expression continued 3 h at 37 C. Cells were harvested by centrifugation at 4K rpm. Cell pellets were resuspended in 100 mL buffer TE (10 mM
Tris-HCl, 1 mM EDTA, pH 8.0) and lysis was accomplished using a French Press microfluidizer (two passages). The crude extract, containing BACEl as insoluble inclusion bodies, was centrifuged at 14K rpm for 15 minutes, and the resulting pellet washed by resuspension in PBS (10 mM sodium phosphate, 150 mM NaCl, pH 7.4) followed by centrifugation at 14K rpm for 20 minutes. Washed inclusion body pellets were solubilized in 50 mM CAPS, 8 M urea, | mM
EDTA, and 100 mM [-mercaptoethanol, pH 10, and remaining insoluble debris removed by centrifugation at 20K rpm for 30 minutes. BACE! was refolded by slow injection of the urea- solubilized protein to between 50 and 100 volumes of rapidly stirred water, or 10 mM Na,CO,, pH 10, followed by incubation at room temperature for 3-7 days. When BACE1 enzymatic activity no longer increased over time, the pH of the refolding solution was adjusted to 8.0 by addition of 5 mM (final concentration) Tris-HCI, and loaded onto a Q-Sepharose column. Protein was eluted using a linear gradient of 0 to 500 mM NaCl in 10 mM Tris-HCI, pH 8.0. BACE!1 was further purified by S-Sepharose chromatography at pH 4.5. Purified enzyme was dialyzed versus 20 mM
Tris, 0.125 M NaCl, pH 7.2 at 4 C, and stored at 4 C. Protein concentrations were determined by absorbance at 280nm, using £250 © = (0.74).
EXAMPLE 10
CLONING AND MUTAGENESIS OF MITOGEN-ACTIVATED PROTEIN
KINASE/EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE (MEK)
Mek-1 (accession number SWS Q02750) is a dual specificity kinase that plays a key role in cellular proliferation and survival in response to mitogenic stimuli. Mek-1 is the central component of a three-kinase cascade commonly called a MAP kinase cascade. This Raf-Mek-Erk kinase cascade transmits information from cell surface receptors (e.g. EGFR, HER2, PDGFR, FGFR, IGF, etc.) to the nucleus. This pathway is upregulated in approximately 30% of all tumor types, either through : overexpression of specific cell surface receptors (e.g. HER2 in breast cancers) or through activating mutations in Ras, a key upstream component of this pathway. Disruption of Mek-1 function has : dramatic anti-tumor effects, both in cell culture and in animals. Mek-2 (accession number SWS P36507) is a dual specificity kinase that is both highly homologous (79% identity) to Mek-1 and coordinately expressed with Mek-1. Thus, Mek-1 and Mek-2 represent attractive targets for the development of novel anti-cancer therapeutics. There are no crystal structures to date for Mek-1 or
Mek-2. } Cloning of human Mek-1 and Mek-2
Numbering of the wild type and mutant Mek-1 and Mek-2 residues begins at their respective amino . termini, with residue number 1 being the initiation methionine, according to the NCBI reported sequences (NCBI accession number 105624 for Mek-1 and NCBI accession number HUMMEK2F for Mek-2). All standard cloning and mutagenesis steps were carried out according to the recommendations of the enzyme manufacturer.
The DNA encoding human Mek-1 was isolated from plasmid pUSE MEK] (Upstate
Biotechnology) and inserted into plasmid pGEX-4T-1 (Amersham) in frame with GST as follows.
First, pUSE MEK1 was digested with Not] (New England Biolabs), the 3’ overhang filled in with the Klenow fragment of DNA polymerase (New England Biolabs), and the 1193 bp product encoding MEK was isolated from an agarose gel. pGEX-4T-1 was linearized by digestion with
EcoRI (New England Biolabs) and the 3’ overhang similarly filled in with the Klenow fragment of
DNA polymerase (New England Biolabs). The MEK1 and pGEX-4T-1 DNA fragments were then ligated with T4 ligase and amplified in E. coli strain Topl0F’ (Invitrogen) to generate plasmid pGEX-MEKI.
The DNA encoding human Mek-2 was isolated from plasmid pUSE MEK2 (Upstate
Biotechnology) and inserted into plasmid pGEX-4T-1 (Amersham) in frame with GST as follows.
First, pUSE MEK2 was digested with Notl (New England Biolabs), the 3’ overhang filled in with the Klenow fragment of DNA polymerase (New England Biolabs), and the 1213 bp product encoding MEK2 was isolated from an agarose gel. pGEX-4T-1 was linearized by digestion with
EcoRI (New England Biolabs) and the 3’ overhang similarly filled in with the Klenow fragment of
DNA polymerase (New England Biolabs). The MEK2 and pGEX-4T-1 DNA fragments were then ligated with T4 ligase and amplified in E. coli strain ToplOF’ (Invitrogen) to generate plasmid pGEX-MEK2.
Generation of Mek-1 and Mek-2 Cysteine Mutants
All mutagenesis steps were performed using long range PCR. Reactions contained the parent plasmid (2 ng/pl), sense strand mutant primer (0.5 pM), and antisense strand mutant primer 0.5 uM) that are unique to each reaction. In addition, all reactions contained dNTPs (25 pM) and Pfu polymerase (0.05 Units/pl; Stratagene). Reactions were incubated for one minute at 95 C followed by 16 cycles of (0.5 minutes at 95 C, 1 minute at 55 C, and 2 minutes at 68 C) and a final 10 minutes at 68 C. Parent plasmid DNA was then digested with Dpnl (New England Biolabs) and the remaining linear PCR product was transformed into E. coli strain ToplOF’ (Invitrogen).
Mutagenized plasmid DNA, the result of in vivo recombination and subsequent amplification, was purified using QIAquick (Qiagen) columns and verified by sequencing.
First, a 6xHIS epitope tag was introduced into pGEX-MEK]1, at the carboxy terminus of MEK to generate pGEX-MEKI-HIS using the sense and antisense oligonucleotides MEK 1-6HIS-s and
MEK 1-6HIS-as, resepectively. Similarly, a 6xHIS epitope tag was introduced into pGEX-MEK2, at the carboxy terminus of MEK2, to generate pGEX-MEK2-HIS using the sense and antisense oligonucleotides, MEK2-6HIS-s and MEK2-6HIS-as, resepectively.
MEK1-6HIS-s
CACGCTGCCAGCATCGGCGTCGACCCAACCCTGGTT
CCGCGTGGATCCCATCACCATCACCATCACTGAGCG
GCCAATTCCCGG
SEQ ID NO:193
MEK1-6HIS-as
CCGGGAATTGGCCGCTCAGTGATGGTGATGGTGATG
GGATCCACGCGGAACCAGGGTTGCGTCGACGCCGAT
GCTGGCAGCGTG
SEQ ID NO:194
MEK2-6H]IS-s
ACGCGTACTGCAGTGGGCGTCGACCCAACCCTGGTT
CCGCGTGGATCCCATCACCATCACCATCACTGAGCG
GCCAATTCCCGG
SEQ ID NO:195
MEK?2-6HIS-as
CCGGGAATTGGCCGCTCAGTGATGGTGATGGTGATG
GGATCCACGCGGAACCAGGGTTGGGTCGACGCCCAC
TGCAGTACGCGT
SEQ ID NO:196
Subsequently, 16 individual mutations were introduced into pGEX-MEKI1-HIS. Similarly, the analogous 16 individual mutations were introduced into pGEX-MEK2-HIS. Each of these mutations introduces a cysteine into the MEK1 or MEK2 protein, and each is named according to the resultant amino acid substitution. For example, primer pair MEK 1-N78C-sense and MEK 1-
N78C-antisense were used to introduce a cysteine in place of N78 of MEK], generating pGEX-
MEK 1/N78C-HIS. 40
Mutagenic Oligonucleotides
MEK 1-N78C-s GAGCTGGGGGCTGGCTGCGGCGETGTGRTGTTC SEQ ID
NO:197
MEK 1-N78C-as GAACACCACACCGCCGCAGCCAGCCCCCAGCTC SEQ ID . NO:198
MEK 1-G79C-s CTGGGGGCTGGCAATTGCGGTGTGGTGTTCAAG SEQ iD
NO:199 i MEK1-G79C-as CTTGAACACCACACCGCAATTGCCAGCCCCCAG SEQ ID
NO:200
MEK]1-1107C-s GAGATCAAACCCGCATGCCGGAACCAGATCATA SEQ ID
NO:201
MEK1-1107C-as TATGATCTGGTTCCGGCATGCGGGTTTGATCTC SEQ ID
NO:202
MEK1-R108C-s ATCAAACCCGCAATCTGCAACCAGATCATAAGG SEQ ID
NO:203
MEK1-R108C-as CCTTATGATCTGGTTGCAGATTGCGGGTTTGAT SEQ ID
NO:204
MEK1-I111C-s GCAATCCGGAACCAGTGCATAAGGGAGCTGCAG SEQ ID
NO:205
MEK1-I1111C-as CTGCAGCTCCCTTATGCACTGGTTCCGGATTGC SEQ ID
NO:206
MEKI1-E114C-s AACCAGATCATAAGGTGCCTGCAGGTTCTGCAT SEQ ID
NO:207
MEK1-E114C-as ATGCAGAACCTGCAGGCACCTTATGATCTGGTT SEQ ID
NO:208
MEK1-L118C-s AGGGAGCTGCAGGTTTGCCATGAGTGCAACTCT SEQ ID
NO:209
MEXK1-L118C-as AGAGTTGCACTCATGGCAAACCTGCAGCTCCCT SEQ ID
NO:210
MEK1-V127C-s AACTCTCCGTACATCTGCGGCTTCTATGGTGCG SEQ ID
NO:211
MEK1-V127C-as CGCACCATAGAAGCCGCAGATGTACGGAGAGTT SEQ ID
NO:212
MEK1-M143C-s GAGATCAGTATCTGCTGCGAGCACATGGATGGA SEQ ID
NQO:213
MEK1-M143C- TCCATCCATGTGCTCGCAGCAGATACTGATCTC SEQ ID as NO:214
MEK 1-S150C-s CACATGGATGGAGGTTGCCTGGATCAAGTCCTG SEQ ID
NO:215
MEK1-S150C-as CAGGACTTGATCCAGGCAACCTCCATCCATGTG SEQ ID . NO:216
MEK1-L180C-s AAAGGCCTGACATATTGCAGGGAGAAGCACAAG SEQ ID ) NO:217
MEK1-L180C-as CTTGTGCTTCTCCCTGCAATATGTCAGGCCTTT SEQ ID
NO:218
MEK1-1186C-s ~~ AGGGAGRAGCACAAGTGCATGCACAGAGATGTC SEQ ID
NO:219
MEK1-1186C-as GACATCTCTGTGCATGCACTTGTGCTTCTCCCT SEQ ID
NO:220
MEK1-K192C-s ATGCACAGAGATGTCTGCCCCTCCAACATCCTA SEQ ID
NO:221
MEK1-K192C-as TAGGATGTTGGAGGGGCAGACATCTCTGTGCAT SEQ ID
NO:222
MEK1-S194C-s AGAGATGTCAAGCCCTCCAACATCCTAGTCAAC SEQ ID
NO:223
MEK 1-S194C-as GTTGACTAGGATGTTGCAGGGCTTGACATCTCT SEQ ID
NO:224
MEK1-L197C-s AAGCCCTCCAACATCTGCGTCAACTCCCGTGGG SEQ ID
NO:225
MEK]1-L197C-as CCCACGGGAGTTGACGCAGATGTTGGAGGGCTT SEQ ID
NO:226
MEK1-V211C-s CTCTGTGACTTTGGGTGCAGCGGGCAGCTCATC SEQ ID
NO:227
MEK1-V211C-as GATGAGCTGCCCGCTGCACCCAAAGTCACAGAG SEQ ID
NO:228
MEK2-N82C-s GAGCTGGGCGCGGGCTGCGGCGGGGTGGTCACT SEQ ID
NO:229
MEK2-N82C-as GGTGACCACCCCGCCGCAGCCCGCGCCCAGCTC SEQ ID
NO:230
MEK?2-G83C-s CTGGGCGCGGGCAACTGCGGGGTGGTCACCARAA SEQ ID
NO:231
MEK2-G83C-as TTTGGTGACCACCCCGCAGTTGCCCGCGCCCAG SEQID
NO:232
MEK2-1111C-s GAGATCAAGCCGGCCTGCCGGAACCAGATCATC SEQ ID
NO:233
MEK2-1111C-as GATGATCTGGTTCCGGCAGGCCGGCTTGATCTC SEQ ID
NO:234
MEK2-R112C-s ATCAAGCCGGCCATCTGCAACCAGATCATCCGC SEQ ID
NO:235
MEK2-R112C-as GCGGATGATCTGGTTGCAGATGGCCGGCTTGAT SEQID
NO:236
MEK2-I115C-s GCCATCCGGAACCAGTGCATCCGCGAGCTGCAG SEQ ID
NO:237
MEK2-I115C-as CTGCAGCTCGCGGATGCACTGGTTCCGGATGGC SEQ ID
NO:238 :
MEK2-E118C-s AACCAGATCATCCGCTGCCTGCAGGTCCTGCAC SEQ ID
NO:239 )
MEK2-E118C-as GTGCAGGACCTGCAGGCAGCGGATGATCTGGTT SEQ ID
NO:240
MEK2-L122C-s CGCGAGCTGCAGGTCTGCCACGAATGCAACTCG SEQID
NO:241
MEK?2-L122C-as CGAGTTGCATTCGTGGCAGACCTGCAGCTCGCG SEQ ID
NO:242
MEK?2-V131C-s AACTCGCCGTACATCTGCGGCTTCTACGGGGCC SEQ ID
NO:243 . MEK2-V131C-as GGCCCCGTAGAAGCCGCAGATGTACGGCGAGTT SEQ ID
NO:244 e MEK?2-M147C-s GAGATCAGCATTTGCTGCGAACACATGGACGGC SEQ ID
NO:245
MEK2-M147C- GCCGTCCATGTGTTCGCAGCAAATGCTGATCTC SEQ ID as NO:246
MEK?2-S154C-s CACATGGACGGCGGCTGCCTGGACCAGGTGCTG SEQ ID
NO:247
MEK?2-S154C-as CAGCACCTGGTCCAGGCAGCCGCCGTCCATGTG SEQ ID
NO:248
MEK?2-L184C-s CGGGGCTTGGCGTACTGCCGAGAGAAGCACCAG SEQID
NO:249
MEK?2-L184C-as CTGGTGCTTCTCTCGGCAGTACGCCAAGCCCCG SEQ ID
NO:250
MEK2-1190C-s CGAGAGAAGCACCAGTGCATGCACCGAGATGTG SEQ ID
NO:251
MEK2-1190C-as CACATCTCGGTGCATGCACTGGTGCTTCTCTCG SEQ ID
NO:252
MEK?2-K196C-s ATGCACCGAGATGTGTGCCCCTCCAACATCCTC SEQ ID
NO:253
MEK2-K196C-as GAGGATGTTGGAGGGGCACACATCTCGGTGCAT SEQID
NO:254
MEK?2-S198C-s CGAGATGTGAAGCCCTGCAACATCCTCGTGAAC SEQ ID
NO:255
MEK2-S198C-as GTTCACGAGGATGTTGCAGGGCTTCACATCTCG SEQ ID
NO:256
MEK2-L201C-s AAGCCCTCCAACATCTGCGTGAACTCTAGAGGG SEQ ID
NO:257
MEK2-L201C-as CCCTCTAGAGTTCACGCAGATGTTGGAGGGCTT SEQ ID
NO:258
MEK2-V215C-s CTGTGTGACTTCGGGTGCAGCGGCCAGCTCATA SEQ ID
NO:259
MEK?2-V215C-as TATGAGCTGGCCGCTGCACCCGAAGTCACACAG SEQ ID " NO:260 - Sequencing primers pGEX forward GGGCTGGCAAGCCACGTTTGGTG SEQ ID
NO:261 pGEX reverse CCGGGAGCTGCATGTGTCAGAGG SEQ ID
NO:262
Expression of Mek-1 and Mek-2 mutants
Mutant alleles of Mek-1 and Mek-2 were expressed in E. coli and purified essentially as described for Mek-1 [by McDonald, O. B., et al., Analytical Biochem. 268: 318-329 (1999)]. Plasmids containing the mutant Mek-1 and Mek-2 alleles were transformed into BL21 DE3 pLysS cells (Invitrogen) according to manufacturer’s suggestions. Cultures were grown overnight at 37 C from single colonies in 100 ml 2YT medium supplemented with 100 ug/ml ampicillin and 100 ng/ml chloramphenicol. This culture was then added to 1.5 L 2YT supplemented with 100 pg/ml ampicillin to achieve an OD of approximately 0.05 and then grown to an OD, of approximately 0.7at30 C. Expression was induced with the addition of IPTG to a final concentration of 1 mM and the culture was incubated for four hours at 25 C. Cells were pelleted in a Sorfall GSA rotor at 6K rpm for 15 minutes and stored at —80 C.
Mek-1 and Mek-2 mutants were purified from cells by first resuspending cell pellets in ice cold
PBS containing 0.5% Triton X-100 and incubating on ice for 45 minutes, followed by extensive sonication. Lysates were clarified by centrifugation in a Sorvall GSA rotor at 12K rpm for one hour. Fusion proteins were first purified on Ni-NTA resin (Qiagen) according to manufacturer’s suggestions, followed by further purification on glutathione agarose as described [by McDonald, O.
B., et al., Analytical Biochem. 268: 318-329 (1999)]. Epitope tags were removed with thrombin cleavage and aliquots of purified protein were stored at -80 C in TBS containing 10% glycerol.
EXAMPLE 11
CLONING AND MUTAGENESIS OF HUMAN CATHEPSIN S (CATS)
Cathepsin S (accession number SWS P25774) is a thiol protease located primarily in the lysosome.
This enzyme plays roles in antigen presentation by processing of the MHC-II antigen receptor; thus inhibitors to the enzyme could be used for diseases such as inflammation and autoimmunity such as rheumatoid arthritis, multiple sclerosis, asthma and organ rejection. It has also been reported that cats is present in increased levels in the Alzheimer’s disease and Down Syndrome brain compared with normal brain. A structural model of cathepsin S [IBXF, Fengler, A. & Brandt W., Protein
Eng 11:1007-1013(1998)] and a crystal structure of the C25S mutant [Turkenburg, J. P. et al. Acta
Crystallogr D Biol Crystallog 58: 451-455 (2002)] are available. :
Cloning of human catS .
The DNA sequence encoding human cathepsin S (catS) was isolated by PCR from the plasmid pDualGC (Stratagene #E01089) using PCR primers listed below corresponding to the protein N- and C-termini. These primers were designed to contain restriction endonuclease sites EcoRI and
Xhol, for subcloning into a modified pFastBac vector, pFBHT (c.f. example 4 above). SEQ ID
NO: 263 was used with SEQ ID NO: 264 and SEQ ID NO 265 to make catS with and without a 6xhis tag, respectively. . 5° CatS EcoRI CCGGAATTCATGAAACGGCTGGTTTGTGTGCT SEQ ID NO:263 3’ CatS Xhol CCCCGCTCGAGGATTTCTGGGTAAGAGGGAAAG SEQ ID NO:264 3'CatS Xhol stop ~ CCCCGCTCGAGCTAGATTTCTGGGTAAGAGGGAAA SEQ ID NO:265
The PCR reaction was purified on a Qiaquick PCR purification column (Qiagen). The PCR product containing the catS sequence was cut with restriction endonucleases (42 ul PCR product, 1 ul each endonuclease, 5 ul appropriate 10x buffer; incubated at 37 C for 3 hours). The pFBHT vector was cut with restriction endonucleases (5 ug DNA, 1 pl each endonuclease, 3 pl appropriate 10x buffer, water to 30 pl; incubated at 37 C for 3 hours; added 1 pul CIP and incubated at 37 C for 60 minutes). The products of nuclease cleavage were isolated from an agarose gel (1% agarose, TBE buffer) and ligated together using T4 DNA ligase (50 ng pFBHT vector and 50 ng catS PCR product in 10 pl, 10 ul 2x ligase buffer (Roche), 1 ul ligase, incubated at 25 C for 15 minutes). 1 pl of the ligation reaction was transformed into Library Efficiency Chemically Competent DH5a cells (Invitrogen) (1 pl ligation reaction, 100 ul competent cells; incubated at 4 C for 30 minutes, 42 C for 45 seconds, 4 C for 2 minutes, then 900 ul SOC media was added and incubated for 1 hour with shaking at 225 rpm at 37 C), and plated onto LB/agar plates containing 100 pg/ml ampicillin.
After incubation at 37 C overnight, single colonies were grown in 3 ml LB media containing 100 pg/ml ampicillin for 8 hours. Cells were then isolated and double-stranded DNA extracted from the cells using a Qiagen DNA miniprep kit. Sequencing of catS gene was accomplished using M13/pUC Forward and Reverse Amplification Primers (Invitrogen # 18430-017).
Generation of CatS Cysteine Mutations
Mutations were generated using as previously described [Kunkel T. A., et al., Methods_Enzymol. 154: 367-382 (1987)]. DNA oligonucleotides used are shown below and were designed to hybridize with sense strand DNA from plasmid. Sequences were verified using primers with SEQ
ID NO:74 and SEQ ID NO:75.
Mutagenic Oligonucleotides
Y18C CACAAGAACCTTGACATTTCACTTCAGT SEQ ID NO:266
K64C CACCATTGCAGCCACAGTTTCCATATTT SEQ ID NO:267
N67C CATGAAGCCACCACAGCAGCCTTTGTT SEQ ID NO:268
T72C CTGGAAAGCCGTGCACATGAAGCCACC SEQ ID NO:269
E115C GCCATAAGGAAGGCAAGTGTACTTTGA SEQ ID NO:270
R141C GAAAGAAGGATGACACGCATCTACACC SEQ ID NO:271
F146C ACTTCTGTAGAGGCAGAAAGAAGGATG SEQ ID NO:272
F211C TGGGTAAGAGGGACAGCTAGCAATCCC SEQ ID NO:273
Scrub mutations of the cysteines were also made using the following oligonucleotides.
C12A CACTTCAGTAACAGCCCCTTTCTCTCTC SEQ ID NO:274
C12Y CACTTCAGTAACATACCCTTTCTCTCTC SEQ ID NO:275
C258 CACTGAAAGCCCAGGAAGCACCACAAGA SEQ ID NO:276
C110A CAGTGTACTTTGAAGCTGTGGCAGCACG SEQ ID NO:277
Expression of CatS Mutant Proteins
All CatS-FBHT plasmids were site-specifically transposed into the baculovirus shuttle vector (bacmid) by transforming the plasmids into DH10bac (Gibco/BRL) competent cells as follows: 1 ul DNA at 5 ng/pl, 10pt 5x KCM {0.5 M KCl, 0.15 M CaCl,, 0.25 M MgCl], 30 pl water was mixed with 50 ul PEG-DMSO competent cells, incubated at 4 C for 20 minutes, 25 C for 10 minutes, added 900 pl SOC and incubated at 37 C with shaking for 4 hours, then plated onto
LB/agar plates containing 50 ug/ml kanamycin, 7 pg/ml gentamycin, 10 ug/ml tetracycline, 100 pg/ml Bluo-gal, 10 pg/ml IPTG. After incubation at 37 C for 24 hours, large white colonies were picked and grown in 3 ml 2YT media overnight. Cells were then isolated and double-stranded
DNA was extracted from the cells as follows: pellet was resuspended in 250 ul of Solution 1 [15 mM Tris-HCI (pH 8.0), 10 mM EDTA, 100 pg/ml RNase A]. Added 250 ul of Solution 2 [0.2 N
NaOH, 1% SDS) mixed gently and incubated at room temperature for 5 minutes. Added 250 pl 3
M potassium acetate, mixed and placed on ice for 10 minutes. Centrifuged 10 minutes at 14,000x g and transferred supernatant to a tube containing 0.8 ml isopropanol. Mix and place on ice for 10 i minutes. Centrifuge 15 minutes at 14,000x g, wash with 70% ethanol, air dry pellet and resuspended DNA in 40 pul TE.
The bacmid DNA was used to transfect Sf9 cells. Sf9 cells were seeded at 9 x 10° cells per 35 mm well in 2 ml of Sf-900 II SFM medium containing 0.5x concentration of antibiotic-antimycotic and allowed to attach at 27 C for 1 hour. During this time, 5 pl of bacnid DNA was diluted into 100 . ul of medium without antibiotics, 6 ul of CellFECTIN reagent was diluted into 100 pl of medium without antibiotics and then the 2 solutions were mixed gently and allowed to incubate for 30 } minutes at room temperature. The cells were washed once with medium without antibiotics, the medium was aspirated and then 0.8 ml of medium was added to the lipid-DNA complex and overlaid onto the cells. The cells were incubated for 5 hours at 27 C, the transfection medium was removed and 2 ml of medium with antibiotics was added. The cells were incubated for 72 hours at 27 C and the virus was harvested from the cell culture medium.
The virus was amplified by adding 1.0 ml of virus to a 50 ml culture of Sf9 cells at 2 x 10° cells/ml and incubating at 27 C for 72 hours. The virus was harvested from the cell culture medium and this stock was used to express the various catS constructs in High-Five cells. A 1 L culture of High-Five cells at 2 x 10° cells/ml was infected with virus at an approximate MOI of 2 and incubated for 72 hours. Cells were pelleted by centrifugation and the supernatant was dialyzed against 20 L Load buffer (50 mM NaH,PO,, pH 8.0, 300 mM NaCl, 10 mM imidazole), filtered and loaded onto a Ni-NTA (Superflow Ni-NTA, Qiagen) column at 1 ml/min, washed with Load buffer at 2 m}/min and eluted with 50 mM NaH,PO,, pH 8.0, 300 mM NaCl, 250 mM imidazole.
EXAMPLE 12
CASPASE-]
Caspase-1 (accession number SWS P25774), like other caspases exists as an inactive proform, and is proteolytically processed into a large subunit and a small subunit, which then combine to form the active enzyme. An important substrate of caspase-1 is the proform of interleukin-1 (beta).
Caspase-1 produces the active form of this cytokine, which plays a role in processes such as inflammation, septic shock and wound healing. Additionally, active capase-1 induces apoptosis, and plays a role in the progression Huntington’s disease. The structure of caspase-1 has been solved [IBMQ, Okamoto, Y., et al., Chem Pharm Bull (Tokyo), 47:11-21 (1999)].
I-13
IL-13 (accession number SWS P35225), which is produced mainly by activated Th2 cells, shows structural and functional similarities to IL-4. Like IL-4, it increases the secretion of immunoglobulin E by B cells and is involved in the expulsion of parasites. In addition, IL-13 downregulates the production of cytokines including IL-1b, IL-6, TNF-alpha and IL-8 by stimulated monocytes. IL-13 also prolongs monocyte survival, increases the expression of MHC class II and CD23 on the surface of monocytes, and increases expression of CD23 on B cells.
Furthermore, IL-2 and IL-13 synergize in the regulation interferon-gamma synthesis. Due to these effects, IL-13 plays a role in conditions such as allergy and asthma. In particular, a polymorphism at position 130 (Q) increases the risk of asthma development. The structure of IL-13 has been solved by nuclear magnetic resonance (NMR) [1GA3, Eissenmesser, E. Z. et al.. J. Mol. Biol. 310: 231-241 (2001)).
CD40L
CDA40L (accession number SWS P29965) is a protein that is found in two forms. a transmembrane form and also an active, proteolytically processed, extracellular soluble form. The transmembrane form is expressed on the surface of CD4+ T lymphocytes. Like other members of the TNF family, it is forms a homotrimer. CD40L mediates the proliferation of B cells, epithelial cells, fibroblasts, and smooth muscle cells. Binding of CD40L to the CD40 receptor on T cells provides a critical signal for isotype class switching and production of immunoglobulin antibodies. Defects in CD40L lead to an elevation in IgM levels, and an deficiency in all other immunoglobulin subtypes.
Inhibitors to CD40L would find use in the treatment of autoimmune disease and graft rejection. In addition, reduced interaction between CD40L and its receptor reduces the degree of tau hyperphosphorylation in a mouse model of Alzheimer’s disease. The crystal structure of CDA40OL has been solved [1ALY, Karpusas, M., et al., Structure 3:1031-1039(1995), erratum in Structure 3:1046 (1995)].
HUMAN B-CELL ACTIVATING FACTOR (BAKE)
A member of the TNF superfamily, BAFF (accession number SWS Q9Y275) is a homotrimer and found in both transmembrane and soluble forms. The transmembrane form is processed by the furin family of proprotein convertases. BAFF is upregulated by interferon-gamma and downregulated by PMA/ionomycin treatment. BAFF binds to three different receptors. When it binds to the B-cell specific receptor (BAFFR), it promotes survival of B-cells and the B-cell response. Furthermore, both BAFF and a proliferation-inducing ligand (APRIL) bind to the receptors transmembrane activator and CAML interactor (TACI) and B cell maturation antigen (BCMA), forming a 2 ligands-2 receptors pathway that is responsible for stimulation of T-cell and
B-cell function and humoral immunity. Inhibitors of BAFF would serve as therapeutics for autoimmune diseases characterized by abnormal B-cell activity, such as systemic lupus erythematosis (SLE) and rheumatoid arthritis (RA). A structure of the soluble protein is available [1JHS, Liu, Y., et al., Cell, 108: 383-394 (2002)].
TUMOR SUPPRESSOR P53
P53 (accession number SWS P04637), a transcription factor that can suppress tumor growth, binds
DNA as a homotetramer and is activated by phosphorylation of a serine residue. There are two
\ mechanisms of tumor suppression, depending upon the cell type: induction of growth arrest and activation of apoptosis. P53 controls cell growth by regulating expression of a set of genes; for example, it increases the transcription of an inhibitor of cyclin-dependent kinases. Apoptosis } results from the p53-mediated stimulation of Bax or Fas expression, or the decrease in Bcl2 expression. P53 is mutated or inactivated in about 60% of known cancers, and is also often . overexpressed in a variety of tumor tissues. Reversible inhibitors of p53 could bé used as an adjunct to conventional radio- and chemotherapy to prevent damage to normal tissues during treatment and its severe side effects. Such an inhibitor was shown to protect mice from lethal doses of radiation without the promotion of tumor formation. There is a crystal structure of human p53 bound to Xenopus laevis mdm2 protein [1 YCQ, Kussie, P. H., et al., Science 274: 948-953 (1996)].
P33-BINDING PROTEIN MDM?
In response to DNA damage, p53 increases the transcription of the protein mdm2 (accession number SWS Q00987). In a form of negative feedback, mdm2 inhibits p53-induced cell cycle arrest and apoptosis by two means. Firstly, mdm2 binds the transcriptional activation domain of p33, reducing its transcriptional activation activity. Secondly, in the presence of ubiquitin E1 and
E2, mdm2 serves as an ubiquitin protein ligase E3 for both itself and p53. The ubiquitination of p53 allows its export from the nucleus to the proteasome, where it is destroyed. There are eight isoforms of mdm? that are produced by alternative splicing. They are mdm2, mdm2-A, mdm2-Al, mdm2-B, mdm2-C, mdm2-D, mdm2-E, and mdm2-alpha. Of these, mdm2-A, mdm2-B, mdm2-C, mdm2-D, and mdm2-E are observed in human cancers but not in normal tissues. Mdm?2 amplification has also been observed in certain tumor types, including soft tissue sarcoma, osteosarcoma, and glioblastoma. These tumors often contain wild type pS3. Small molecule inhibitors of mdm2 could promote the proapoptotic activity of the wild type p53 and find use in cancer therapy. The structure of Xenopus laevis mdm2 in complex with human p53 has been solved [1YCR, Kussie, P. H. et al., Science 274: 948-953 (1996)].
BCL-X
Bcl-x (accession number SWS Q07817) is a member of the Bel2 family of proteins and has two major isoforms produced by alternative splicing, bcl-x(L), bel-x(S). The long isoform, bel-x(L) is found in long-lived postmitotic cells and inhibits apoptosis, whereas the short isoform, bel-x(S), is found in cells with a high turnover rate and promotes apoptosis. The long isoform inhibits apoptosis by binding to voltage-dependent anion channel (VDAC) and preventing the release of apopotosis activator cytochrome ¢ from the mitochondrial membrane. This antiapoptotic activity is dependent upon the BH4 (bcl-2 homology) domain of Bel-x(L); binding of this protein to other
Bcl2 family members is dependent upon the BH1 and BH2 domains. Expression of Bcl-x(L) has been observed to be expressed primarily by the neoplastic cells in a majority of lymphoma cases.
= oo
Inhibition of bcl-x(L) expression in several cell lines resulted in apoptosis. Thus, due to its antiapoptotic effects, bel-x(L) is a target for cancer therapeutics. Interestingly, binding of Bcel-x(L) to another Bcl2 family member, the proapoptotic protein Bax, results in an increase in apoptosis (see below). A crystal structure of Bcl-x(L) has been solved [IMAZ, Muchmore, S. W., et al.
Nature 381: 335-341 (1996)].
BAX
Bax {accession number SWS Q07812 (BAX alpha); SWS Q07814 (BAX beta); SWS Q07815 (BAX gamma); SWS P55269 (BAX delta)] promotes apoptosis by binding to the antiapoptotic protein bel-x(L), inducing the release of cytochrome c, and activating caspase-3. Bax has several isoforms produced by alternative splicing; some are membrane bound and others are cytoplasmic.
The BH3 domain of Bax is necessary for its binding to members of the anti-apoptotic Bcl2 family.
Defects in Bax are observed in some cell lineages from hematopoietic cancers. Bax agonists could be used in cancer therapies, while Bax inhibitors could be used to counteract neuronal cell death resulting from ischemia, spinal cord injury, Parkinson's disease and Alzheimer’s disease. An NMR structure of BAX has been solved [1F16, Suzuki, M., et al., Cell 103:645-654 (2000)).
CDC25A
CDC25A (accession number SWS P30304) is a dual-specificity phosphatase also known as M- phase inducer phosphatase 1 (MPI1). Induced by cyclin B, CDC25A is required for progression of the cell cycle, and induces mitosis in a dosage-dependent manner. CDC25 directly dephosphorylates CDC2, thereby decreasing its activity. It has also been demonstrated in vitro that
CDC25 dephosphorylates CDK2 in complex with cyclinE. Elevated levels of CDC25 can trigger uncontrolled cell growth and are linked with increased mortality in breast cancer patients.
Activated CDC25A is also observed in degenerating neurons of the Alzheimer’s diseased brain. A structure of the catalytic core has been solved [1C25, Fauman, F. B., et al., Cell 93: 617-625 (1998)].
CD28
CD28 (accession number SWS P10747) is a disulfide-linked homodimeric transmembrane protein expressed on activated B-cells and a subset of T-cells. This protein can bind three others: B7-1,
B7-2, and CTLA-4. The interaction of CD28 with B7-1 and B7-2 present on the surface of antigen presenting cells (APCs) results in a co-stimulation of naive T-cell activation, whereas subsequent interaction of the same B7-1 and B7-2 molecules with CTLA-4 leads to an attenuation of the T-cell stimulation. CD28-associated signaling pathways are important therapeutic targets for autoimmune disease, graft vs. host disease (GVHD), graft rejection, and promotion of immunity against tumors.
The structure of CD28 has not been solved to date.
B7
There are 2 B7 proteins: B7-1 (accession number SWS P33681), also known as CD80, and B7-2 (accession number SWS P42081), also known as CD86. Both are highly glycosylated . transmembrane proteins expressed on activated B-cells. Early events in immune response are controlled by the interactions of these molecules with CD28 and CTLA-4 (see above). Thus B7-1 . and B7-2 make significant targets for therapeutics treating autoimmune disease. A structure of the soluble form of B7-1 has been solved [IDR9, Ikemizu, S., et al., Immunity 12: 51-60 (2000)] in addition to a structure of B7-1 in complex with CTLA-4 [118L, Stamper, C. C., et al., Nature 410: 608-611 (2001)]. In addition, a structure of B7-2 in complex with CTLA-4 has been solved [1185,
Schwartz, J.-C. D., et al., Nature 410: 604-608 (2001).
CSA
The immune system comprises in part the complement cascade, which is a set of more than 20 proteins. C5a is one of these complement proteins; it is a cytokine-like activation product of CS. CS5a effects inflammation, and specifically has a role in the recruitment of neutrophils in response to bacterial infection. In sepsis, the life threatening spread of bacterial toxins through the blood, the effects of C5a are exhausted, due to an overexposure of the neutrophils to excessive amounts of this complement protein. Furthermore, expression levels of C5a receptor (accession number SWS
P21730) are increased in certain vital organs during sepsis. Thus inhibitors of C5a or the C5a receptor could help in treating sepsis. Inhibitors of C5a could also be used in the treatment of bullous pemphigoid, the most common autoimmune blistering disease. Another effect of C5a is its synergy with the Abeta peptide to promote secretion of IL-1 and IL-6 in human macrophage-like
THP-1 cells; C5a may therefore be involved in the pathogenesis of Alzheimer’s disease. Although the structure of C5a has been solved by NMR [1KIJS, Zhang, X, et al., Proteins 28: 261-267 (1997)], there is no structure of the C5a receptor to date.
AKT
Akt is an important component of the signaling pathway of growth factor receptors. There are three highly related Akt genes, Akt 1-3 (accession numbers SWS P31749, Aktl; SWS P31751, Akt2;
SWS Q9Y243), which show compensatory effects for one another. However, they have different expression patterns, suggesting that each may have unique functions as well. Each Akt is activated by phosphorylation of multiple residues and is activated by the kinase ILK. Binding of activated
Akt to PI3K (phosphatidyl inositol 3-kinase) causes the translocation of the active Akt to the plasma membrane. Akt has pleiotropic effects leading to cell survival. Additionally, Akt amplification and elevated levels of Akt have been found in some types of cancers. A crystal structure of the kinase domain of Akt2, also known as PXB-8, has recently been obtained [Yang, J., et al., Molecular Cell 9: 1227-1240 (2002)]."
CD45
CD45 (accession number SWS P08575) is a receptor protein tyrosine phosphatase that is primarily located in the plasma membrane of leukocytes; it has several isoforms differing in the extracellular domain, the significance of which is presently unknown. Substrates for CD45 include the kinases lye, fyn, and other src kinases. Additionally, CD45 engages in noncovalent interactions with the lymphocyte phosphatase associated protein (LPAP). CD45 is critical for activation through the antigen receptor on T cells and B cells, and may also be important for the antigen-mediated activation 1n other leukocytes. Dimenzation of CD45 disables its function. Inhibitors of CD45 could be used to prevent allograft rejection. There is no structure of CD45 to date.
HER-2 (accession number SWS P04626), otherwise known as ErbB2 is a receptor tyrosine kinase that is related to EGFR (ErbBl). Although there are no known ligands for HER-2 in isolation, when HER-2 dimerizes with other members of the ErbB family, i.e., ErbB1, ErbB3 and ErbB4, the dimeric complex can bind to a number of ligands. These ligands include heregulins, EGF, betacellulin, and NRG, although binding depends upon which ErbB proteins are in the heterodimer.
Ligand binding increases the phosphorylation of HER-2, and effects subsequent intracellular signaling steps. HER-2 is frequently overexpressed in breast cancer cells, and this overexpression may mediate their proliferation. Breast cancer cells overexpressing HER-2 are also more responsive to HER-2 inhibitors. HER-2 is also implicated in a number of other cancers, such as ovarian, prostate, lung, fallopian tube, osteosarcoma, and childhood medulloblastoma. The structure of this receptor has not yet been solved.
HUMAN GLYCOGEN SYNTHASE KINASE-3 (GSK-3) GSK-3 (accession numbers SWS P49840, GSK-3a; SWS P49841, GSK-3p) is involved in the hormonal control of Myb, glycogen synthase, and c-jun. The phosphorylation of c-jun by GSK-3 decreases the affinity of c-jun for DNA. . Additionally, GSK-3 is phosphorylated by ILK-1 and
Akt-1. Phosphorylation by Aktl causes the inhibition of catalytic activity of GSK-3, which normally phosphorylates cyclin D, thereby targeting cyclin D for destruction. The net effect of this phosphorylation of GSK-3 is the promotion of cell survival. Increased GSK-3 activity has been found in tissue from diabetic patients, consistent with its role in the development of insulin resistance. Furthermore, GSK-38 is overexpressed in the Alzheimer’s disease brain, and this overexpression is associated with tau protein hyperphosphorylation, a hallmark of the disease.
Finally, the effects of some mood-stabilizing drugs such as lithium appear to be mediated by inhibition of GSK. Therefore it is possible that GSK-3 inhibitors would increase the effectiveness of some psychoactive drugs. There is a structure available for GSK-3p [1HS8F, Dajani, R., et al.,
Cell 105: 721-732 (2001)].
ALPHA-E/BETA-T
The protein complex alpha-E/beta-7 is a transmembrane integrin that plays a role in lymphocyte migration and homing. Specifically, the complex serves as a receptor for E-cadherin. Alpha-E . (accession number SWS P38570) is made up of two subunits, a and p, the o-subunit itself is composed of a light chain and a heavy chain linked by a disulfide bond. Likewise, beta-7 . (accession number SWS P26010) is also composed of «- and B- subunits. The alpha-E/beta-7 complex normally mediates the adhesion of intra-epithelial T lymphocytes to mucosal epithelial cell layers; it also plays a role in the dissemination of non-Hodgkin’s lymphoma. Furthermore, a possible mechanism of inflammation involves migration of lymphocytes from the gut epithelium to other parts of the body. Changes in alpha-E/beta-7 levels have been observed in a variety of diseases. Elevated levels of this integrin have been observed in patients with Systemic Lupus
Erythematosus (SLE), in the lung epithelium of patients with interstitial lung disease, and in the siovial fluid of patients with rheumatoid arthritis. Altered patterns of alpha-E/beta-7 expression have been observed in patients with Crohn’s disease, and antibodies to this complex were shown to prevent immunization-induced colitis in a mouse model. Hence, inhibitors to this complex would be valuable in the treatment of inflammation, especially mucosal inflammation. There are no structures available for alpha-E or beta-7.
TISSUE FACTOR
Human tissue factor (accession number SWS P13726), also known as thromboplastin, is an mtegral transmembrane protein that is normally located at the extravascular cell surface. Upon injury to the skin, tissue factor is exposed to blood and complexes with the active form of coagulation enzyme
Factor VII, known as Factor VIIA (see below). Tissue factor can bind both the inactive and active forms of coagulation Factor VII, and is an obligate cofactor for Factor VIIA in triggering the coagulation cascade. Furthermore, since Tissue Factor plays a major role in thrombosis, inhibition of this factor would be expected to decrease the risk for clinical outcomes of thrombosis such as atherosclerosis, arterial occlusion, stroke, and myocardial infarction. A structure of the extracellular domain of tissue factor has been solved [2HFT, Muller, Y. A., et al., J Mol Biol 256:144-159 (1996)]. , FACTOR VII
Factor VII (accession number SWS P08709) is the zymogen (inactive precursor) form of the serine protease coagulation Factor VIIa. More than 99% of this protease circulates in the inactive single- chain form; upon cleavage of an Arg-Ile peptide bond by one of several factors, the active two- chain form is produced. This two-chain form comprises a heavy chain and a light chain, linked by a disulfide bond. Enzymatic carboxylation of Glu residues in Factor VII, which is dependent upon vitamin K, allows the protein to bind calcium. In the presence of calcium and the cofactor human tissue factor (see above), Factor Vila cleaves Factor X and Factor IX to produce their respective active forms, which propagate the coagulation cascade.
Defects in Factor VII can lead to bleeding disorders, where recombinant Factor VIIa finds use as a treatment.
Conversely, some polymorphisms of the Factor VII gene have been associated with an increased risk for myocardial infarction, which is often caused by blood clots.
Factor VII inhibitors are expected to find use in preventing heart disease.
A structure of the zymogen form of factor VII in complex with an .
inhibitory peptide has been solved [1JBU, Eigenbrot, C., et al., Structure 9:627-636 (2001))].
Claims (26)
1. A method comprising: a) obtaining a set of coordinates of a three dimensional structure of a protein target biological molecule (TBM) having » number of residues; b) selecting a candidate residue i on the three dimensional structure of the TBM wherein the candidate residue i is the ith residue where i is a number between 1 and » and residue i is not a cysteine; c) selecting a residue j where residue j is adjacent to residue 7 in sequence; d) determining a candidate reference value wherein the candidate reference value is a spatial relationship between residue i and residue j; e) obtaining a database comprising sets of coordinates of disulfide-containing protein fragments wherein each fragment comprises at least a disulfide-bonded cysteine and a first adjacent residue where the disulfide-bonded cysteine and the first adjacent residue share the same sequential relationship as residue 7 and residue j; f) determining a comparative reference value for each fragment wherein the comparative reference value is the corresponding spatial relationship between the disulfide-bonded cysteine and the first adjacent residue as the candidate reference value is between residue i and j; and, 2) determining a score wherein the score is a measure of the number of fragments in the database that possess a comparative reference value that is the same or similar to the candidate reference value.
2. The method of claim 1 further comprising: selecting a residue k where residue k is adjacent to residue i in sequence and k is not j; and wherein the candidate reference value is a spatial relationship between residue 7, residue j, and residue k; each fragment comprises at least a disulfide-bonded cysteine, a first adjacent residue, and a second adjacent residue where the disulfide-bonded cysteine and the first and second adjacent residues share the same sequential relationship as residue 7, residue j, and residue k; and the comparative reference value is the corresponding spatial relationship between the disulfide bonded cysteine, the first adjacent residue, and the second adjacent residue as the candidate reference value is between residue i, residue j, and residue £. 73 Amended Sheet — 11-03-2005
3. A method comprising: a) obtaining a set of coordinates of a three dimensional structure of a protein target biological molecule (TBM) having » number of residues; b) selecting a candidate residue i on the three dimensional structure of the TBM wherein the candidate residue i is the ith residue where i is a number between 1 and » and residue i is not a cysteine; c) selecting residue j and residue k wherein residue j and residue & are both adjacent in sequence to residue i; d) determining a candidate reference value wherein the candidate reference value is a spatial relationship of at least one backbone atom from each of residue i, residue j, and residue k; €) obtaining a database comprising sets of coordinates of disulfide-containing protein fragments wherein each fragment comprises at least a disulfide-bonded cysteine, a first adjacent residue, and a second adjacent residue where the disulfide-bonded cysteine, the first adjacent residue, and the second adjacent residue share the same sequential relationship as residue 7, residue j, and residue k; f) determining a comparative reference value for each fragment wherein the comparative reference value is the corresponding spatial relationship between the disulfide-bonded cysteine, the first adjacent residue, and the second adjacent residue as the candidate reference value is between residue i, residue j, and residue k; and, 2) determining a score wherein the score is a measure of the number of fragments in the database that possess a comparative reference value that is the same or similar to the candidate reference value.
4. The method of any one of claims 1-3 wherein the spatial relationship comprises a dihedral angle.
5. The method of any one of claims 1-3 wherein the spatial relationship comprises a pair of phi psi angles.
6. The method of any one of claims 1-3 wherein the spatial relationship comprises a plurality of distances between atoms of two residues. 74 Amended Sheet — 11-03-2005
7. The method of any one of claims 1-3 wherein residue i is at least partially surface accessible.
8. The method of claim 7 wherein residue 7 has an accessible surface area of at least about 20 A”.
9. The method of any one of claims 1-3 wherein residue i does not participate in a hydrogen bond interaction with a backbone atom of the TBM.
10. A method comprising: a) obtaining a three dimensional structure of a target biological molecule (TBM) having » number of residues and a site of interest; b) selecting a candidate residue i that is at or near the site of interest wherein the candidate residue i is the ith residue where i is a number between 1 and » and residue 7 is not a cysteine; c) generating a set of mutated TBM structures wherein each mutated TBM structure possesses a cysteine residue instead of residue i and wherein the cysteine residue is placed in a standard rotamer conformation; and, d) evaluating the set of mutated TBM structures.
11. The method of claim 10 wherein the cysteine residue is capped with a S-methyl group.
12. The method of claim 10 wherein the standard rotamer conformation for cysteine comprises: a chil angle selected from the group consisting of about 60°, about 180°, and about 300°; and a chi2 angle selected from the group consisting of about 60°, about 120°, about 180°, about 270°, and about 300°.
13. The method of claim 10 wherein the evaluation step comprises determining whether each rotamer conformation makes an unfavorable steric contact with the TBM.
14. The method of claim 10 wherein the evaluation step comprises a force field calculation.
15. The method of claim 11 wherein the evaluation step comprises determining whether each rotamer conformation places the methyl carbon of the S-methyl group closer to the site of interest than the Cp. 75 Amended Sheet - 11-03-2005
16. A set of variant proteins, said proteins each being a mutated version of a target biological molecule (TBM) wherein a naturally occurring non-cysteine residue of the TBM is mutated into a cysteine, wherein the set comprises at least 3 mutants,
17. The set of claim 16 comprising at least 5 cysteine mutants.
18. The set of claim 16 wherein one or more naturally occurring cysteines of the TBM is mutated to a non-cysteine residue.
19. The set of claim 16 wherein the TBM is a cell surface or soluble receptor.
20. The set of claim 16 wherein the TBM is a cytokine.
21. The set of claim 16 wherein the TBM is an enzyme.
22. The set of claim 16 wherein the TBM is selected from the group consisting of IL-2; IL-4; TNF- a; IL-1 receptor; caspase-3; PTP-1B; HIV integrase; BACE1; MEK-1; Cat-S; caspase-1; IL-13; CD40L; BAFF; P53; mdm?2; bcl-x; bax; CDC25A; CD28; B7; C5A; AKT; CD45; HER2; GSK-3; alpha-E/beta-7; tissue factor; and Factor VIL
23. A set of variant proteins, said proteins each being a mutated version of a target biological molecule (TBM) wherein a naturally occurring non-cysteine residue of the TBM is mutated into a cysteine, and wherein the TBM is a kinase.
24. The set of claim 23 comprising at least 3 cysteine mutants.
25. The set of claim 23 wherein one or more naturally occurring cysteines of the TBM is mutated to’ a non-cysteine residue.
26. The set of claim 23, wherein the TBM is Lck, Syk, Zap-70, JAK, FAK, ITK, BTK, MEK, MEKK, GSK-3, Raf, tgf-B-activated kinase-1 (TAK-1), PAK-1, cdk4, Akt, PKC 6, IKK B, IKK-2, PDK, ask, nik, MAPKAPK, p90rsk, p70s6k, and PI3-K (p85 and p110 subunits). 76 Amended Sheet — 11-03-2005
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31072501P | 2001-08-07 | 2001-08-07 | |
US09/981,547 US20020022233A1 (en) | 1998-06-26 | 2001-10-17 | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US09/990,421 US6919178B2 (en) | 2000-11-21 | 2001-11-21 | Extended tethering approach for rapid identification of ligands |
US10/121,216 US6998233B2 (en) | 1998-06-26 | 2002-04-10 | Methods for ligand discovery |
PCT/US2002/024921 WO2003014308A2 (en) | 2001-08-07 | 2002-08-05 | Cysteine mutants and methods for detecting ligand binding to biological molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200400342B true ZA200400342B (en) | 2005-03-30 |
Family
ID=59676910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2004/00342A ZA200400342B (en) | 2001-08-07 | 2004-01-16 | Cysteine mutants and methods for detecting ligand binding to biological molecules |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200400342B (en) |
-
2004
- 2004-01-16 ZA ZA2004/00342A patent/ZA200400342B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pirozzi et al. | Identification of novel human WW domain-containing proteins by cloning of ligand targets | |
Hopkins et al. | Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. | |
Lin et al. | The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif | |
US20030194745A1 (en) | Cysteine mutants and methods for detecting ligand binding to biological molecules | |
WO1998007835A2 (en) | Crystal structures of a protein tyrosine kinase | |
EP1627045A2 (en) | Pyk2 crystal structure and uses | |
EP1525213A2 (en) | Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto | |
Hohwy et al. | Novel prostaglandin D synthase inhibitors generated by fragment-based drug design | |
Martinez-Fonts et al. | A rapid and versatile method for generating proteins with defined ubiquitin chains | |
Seetoh et al. | Disrupting the constitutive, homodimeric protein–protein interface in CK2β using a biophysical fragment-based approach | |
Malchow et al. | The HPK1 inhibitor A-745 verifies the potential of modulating T cell kinase signaling for immunotherapy | |
Guo et al. | Packaging HIV virion components through dynamic equilibria of a human tRNA synthetase | |
Jenkins et al. | Identification of small-molecule inhibitors of human angiogenin and characterization of their binding interactions guided by computational docking | |
NZ530721A (en) | Cysteine mutants and methods for detecting ligand binding to biological molecules | |
Sluis-Cremer et al. | Structure− Activity Relationships of [2 ‘, 5 ‘-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3 ‘-spiro-5 ‘‘-(4 ‘‘-amino-1 ‘‘, 2 ‘‘-oxathiole-2 ‘‘, 2 ‘‘-dioxide) thymine Derivatives as Inhibitors of HIV-1 Reverse Transcriptase Dimerization | |
US20040014140A1 (en) | Methods for identifying allosteric sites | |
ZA200400342B (en) | Cysteine mutants and methods for detecting ligand binding to biological molecules | |
Ulrich et al. | Engineering a “methionine clamp” into Src family kinases enhances specificity toward unnatural ATP analogues | |
AU2002326537A1 (en) | Cysteine mutants and methods for detecting ligand binding to biological molecules | |
Baker et al. | Amino acid substitution at position 99 affects the rate of CRP subunit exchange | |
US20040002145A1 (en) | Crystal structure of liganded cFMS kinase domain | |
US20030235862A1 (en) | Methods of characterizing molecular interaction sites on proteins | |
Ko | Understanding the Role of NEMO in IKK Activation | |
Silva et al. | A previously-unrecognized motif of transcription factor RYBP, hotspot of cancer-related mutations, is essential for the integrity of Polycomb repressive complex 1 | |
廣實万里子 | Enzymological Analysis of STAT6 Signaling Related Proteins and Its Application to the Drug Discovery and Development |